Podcasts about astrazeneca oxford

This week, please join author Keith Channon as he discusses the article "Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex." Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your co-hosts, I'm Dr. Carolyn Lam, associate editor from the National Heart Center and Duke-National University of Singapore. Dr. Greg Hundley: And I'm Dr. Greg Hundley, associate editor, director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Dr. Carolyn Lam: Oh, Greg, today's feature paper, something that's really been discussed a lot in the press and in lay public as well, the risk of myocarditis following sequential doses of the COVID-19 vaccine and SARS-CoV-2 infection by age and sex. Everyone's going to want to tune into that one. But before we get there, shall we go through some of the key papers in today's issue? Dr. Greg Hundley: You bet, Carolyn. How about if I go first? Dr. Carolyn Lam: Please. Dr. Greg Hundley: So Carolyn, this first manuscript involves the world of machine learning and ECG interpretation. And as you know, novel targeted treatments increase the need for prompt hypertrophic cardiomyopathy detection; however, it's low prevalence, 0.5%, and resemblance to common diseases really present challenges. So Carolyn, these authors, led by Dr. Rahul Deo from Brigham and Women's Hospital, sought to develop machine learning models to detect hypertrophic cardiomyopathy and differentiate it from other cardiac conditions using EKGs and echocardiograms with a robust generalizability across multiple cohorts. So Carolyn, what did they do? They used single-institution hypertrophic cardiomyopathy EKG models that were then trained and validated on data from three academic medical centers in the United States and Japan using a federated learning approach, which enables training on distributed data without data sharing. Models were validated on held out test sets for each institution and from a fourth academic medical center and were further evaluated for discrimination of hypertrophic cardiomyopathy from aortic stenosis, long-standing hypertension, and cardiac amyloidosis. And then finally, automated detection was compared to manual interpretation by three cardiologists on a data set with a realistic hypertrophic cardiomyopathy prevalence. Dr. Carolyn Lam: Wow, incredible. So what were the results? Dr. Greg Hundley: Right, Carolyn. So the authors identified 74,476 EKGs for 56,129 patients and 8,392 echocardiograms for 6,825 patients across the four academic medical centers. Now, while ECG models trained on data from each institution displayed excellent discrimination of hypertrophic cardiomyopathy on internal test data, the generalizability was limited, most notably for a model trained in Japan and then subsequently tested in the United States. Now, however, when trained in a federated manner, discrimination of hypertrophic cardiomyopathy was excellent across all institutions, including for phenotypic subgroups. The models further discriminated hypertrophic cardiomyopathy from hypertension, aortic stenosis, and cardiac amyloid. Analysis of ECG and echocardiography paired data from 11,823 patients from an external institution indicated a higher sensitivity of automated HCM detection at a given positive predictive value compared with cardiologists. So Carolyn, in conclusion, federated learning improved the generalizability of models that use EKGs and echocardiograms to detect and differentiate hypertrophic cardiomyopathy from other causes of left ventricular hypertrophy compared to training within a single institution. It will be really interesting to see the future applicability of these methods. Dr. Carolyn Lam: Oh, I'm such a fan of this work. Awesome. Thank you, Greg. My paper, it's a preclinical paper that uncovers a novel mechanism through which GATA4 mutations can lead to heart disease. Dr. Greg Hundley: All right, Carolyn, no quiz this time, I'm just coming right out. I'm reversing the question on the teacher. Tell me, what is GATA4? Dr. Carolyn Lam: I'm glad you asked, Greg. GATA4 is a zinc finger-containing DNA binding transcription factor essential for normal cardiac development and homeostasis in mice and humans, and mutations in this gene have been reported in human heart defects. Now, in today's paper, authors led by Dr. Srivastava from Gladstone Institutes in San Francisco, California, showed that GATA4 regulated cell-type-specific splicing through direct interaction with RNA and the spliceosome in human-induced pluripotent stem cell-derived cardiac progenitors. An unbiased search for GATA4 interacting proteins in these human iPS cells revealed interaction with many members of the spliceosome complex. GATA4 also bound to pre-messenger RNAs in a sequence-specific manner that resulted in generation of alternatively spliced isoforms in human iPS cells. Many of these GATA4-dependent isoforms had distinct functional properties illustrating the importance of the splicing regulation to cardiac function. Dr. Greg Hundley: Wow, Carolyn, another really interesting study from the world of preclinical science. So what's the take home message here? Dr. Carolyn Lam: So these results essentially uncover a previously unrecognized function for GATA4 in regulating alternative splicing through direct RNA interaction. Several genes that have splicing regulated by GATA4 have functional consequences and many are associated with dilated cardiomyopathy, thus suggesting a novel role for GATA4 in achieving the necessary cardiac proteome in normal and stress-responsive conditions. Dr. Greg Hundley: Very nice, Carolyn, wow. Well, my next paper comes to us from back in the world of clinical science and it's from Professor Bertrand Cariou from L'institut du Thorax in Inserm UMR1087. So Carolyn, only a few genes causally related to plasma LDL-C levels have been identified so far, and only one, ANGPTL3, has been causally related to combined hypocholesterolemia. In this study, the authors aim to elucidate the genetic origin of an unexplained combined hypocholesterolemia inherited in four generations of a French family and used next generation sequencing and identified a novel dominant rare variant in the LIPC gene encoding for hepatic lipase, which co-segregates with the phenotype. They characterize the impact of this LIPC-E97G variant on circulating lipid and lipoprotein levels in family members using nuclear magnetic resonance based lipoprotein profiling and lipids. Dr. Carolyn Lam: Wow, what an interesting approach to study patients and families with hypocholesterolemia for once instead of hyper. Interesting. So what did they find? Dr. Greg Hundley: Right, Carolyn. So the investigative team found that this unique LIPC-E97G variant specifically increases the phospholipase activity of hepatic lipase without affecting triglyceride lipase activity. And second, the hypocholesterolemic phenotype related to LIPC-E97G variant is due to an increased clearance of cholesterol within triglyceride-rich lipoprotein remnants predominantly by extrahepatic tissues. Dr. Carolyn Lam: Wow, so what are the implications? Dr. Greg Hundley: Right, Carolyn. So the novel gain of function variant in LIPC potentially represents the second cause of familial combined hypocholesterolemia after loss of function variants in ANGPTL3. And second, this study highlights an unexpected and critical role of the phospholipase activity of hepatic lipase encoded by LIPC in LDL-C metabolism and identifies it as a potential novel drug target. And then finally, Carolyn, additional data, I think, are warranted to clarify the impact of LIPC-E97G-related combined hypocholesterolemia on atherosclerosis and atherosclerotic cardiovascular disease due to the occurrence of documented coronary stenosis and evolutive carotid atherosclerosis in index cases. Dr. Carolyn Lam: Oh, very, very interesting. Thanks, Greg. Well, let's wrap up with the discussion of what else is in today's issue. There's an In Depth paper by Dr. Hadley on protecting cardiovascular health from wildfire smoke. There's also a Research Letter by Dr. Mevorach on myocarditis after BNT162b2 COVID-19 third booster vaccine in Israel. Dr. Greg Hundley: Right, Carolyn. And then I've got an exchange of letters from Professors Condello and Doenst regarding the article Cytokine Hemoadsorption During Cardiac Surgery Versus Standard Surgical Care for Infective Endocarditis from the REMOVE study: Results From a Multicenter Randomized Controlled Trial. Well, how about we get on to that feature discussion and learn a little bit more about COVID-19 vaccine and SARS-CoV-2 infection. Dr. Carolyn Lam: Let's go, Greg, thanks. Dr. Greg Hundley: Listeners, welcome to this September 6th feature discussion. And with us today, very interesting topic pertaining to vaccination for SARS-CoV-2 virus prevention. And we have with us Dr. Keith Channon from Oxford, England, to discuss this very interesting paper. Well, Keith, welcome. I wanted to start by asking you, can you describe for us a little the background information that went into the preparation of your study, and what was the hypothesis that you wanted to address? Dr. Keith Channon: Thanks, Greg, for the opportunity to join you in this interesting conversation today. A group of cardiologists in the UK based at the University of Oxford, and principally at the University of Edinburgh, have been interested in the question as to whether COVID infection and/or COVID vaccination might lead to a higher incidence of myocarditis. And this is a topic that has been the subject of previous publications in the field. And the provocation for us undertaking this study is that those previous studies have tended to be relatively small, and they've also not been able to necessarily test the details, time association, between myocarditis occurring in relation to sequential doses of vaccination. And that's important because, of course, we're now all receiving sequential doses of booster vaccines, and also those vaccines are often delivered, different vaccine types to different people in different countries. So we wanted to test whether there does appear to be a significant association between the occurrence of myocarditis and both COVID infection and the sequential different COVID vaccinations. Dr. Greg Hundley: Very nice. So Keith, can you describe for us, what study population did you enroll for this initiative? And then also, what was your study design? Dr. Keith Channon: Thank you. So, one of the really exciting things about this type of study and probably what makes it unique is that in countries with healthcare system, like that in the UK, which is the National Health Service, and universities, such as the University of Oxford and the University of Edinburgh, where there are very strong academic links between researchers and the National Health Service, we've been able to leverage an enormous data set, which is almost 43 million people in the UK who underwent vaccination against COVID-19. And rather than having to follow up 43 million people as part of a research study, we were able to take advantage of National Health Service centralized coded hospital records, number one. Number two, we took advantage of the UK's national database on COVID vaccination. And number three, we were able to look at hospital outcomes and also COVID testing. So we were able to put together those three data sets for us to understand who developed COVID infection, who received COVID vaccination, and if so, which vaccine and when, and who then was admitted to hospital with a coded diagnosis of myocarditis. And in 43 million people, even though myocarditis is a very uncommon outcome, there were sufficient cases in that very large population to draw statistically meaningful conclusions. I think that the UK is probably one of the few countries where this type of research can be done. And academic organizations, like our universities, the National Health Service, and also cardiovascular research funders, such as the British Heart Foundation, have put in a lot of resource and effort into giving us those capabilities to answer questions like this, and it's turned out to be a very powerful capability. Dr. Greg Hundley: Very nice. And so Keith, can you describe for us your study results? Dr. Keith Channon: So the study looked at a large 43 million people approximately over a period of time during the early to mid-phase of the COVID pandemic and looked at the likelihood that people would be diagnosed with myocarditis following either vaccination or COVID test positive. And we compared that likelihood with the likelihood of myocarditis occurring outside of those periods; because, of course, myocarditis occurs reasonably commonly in the general population. So this is another powerful aspect of the study design. It has a curated approach to look at the incidence of myocarditis in the 28 days after either vaccination or COVID infection, and it corrects, or it controls for that relative to the incidence of myocarditis outside of those sampling periods. And what we found simply is that there is indeed, as previous studies have shown, a small but significant association between receiving a COVID-19 vaccine and being diagnosed with myocarditis in the following 28 days. However, in the population as a whole, the risk of myocarditis after vaccination is substantially lower than the risk of developing myocarditis after COVID infection, and I think that's an important finding. When we looked at subgroups, which is interesting, we found that the highest risk of developing myocarditis was in men less than age 40, so younger men, and that was one finding. And also, there did seem to be some differences in the risk of myocarditis occurring after different sequential vaccine doses. Dr. Greg Hundley: Keith, just a quick clarification point, what vaccines did you examine? Dr. Keith Channon: So in the UK, the three vaccines that have been largely used of the AstraZeneca Oxford viral vaccine, ChAdOx1, which was of course introduced very early in the UK, along with the Pfizer mRNA vaccine, and then laterally, Moderna vaccine, which of course in the UK was brought in rather later. And I think that's interesting because, as we can go on and discuss, there do appear to be some possible differences between those vaccines in terms of the likelihood of being diagnosed with myocarditis afterwards. But of course, even our experiment in 43 million people is not a perfect design because it's an observational study, and the periods in the pandemic when people were receiving principally the first two vaccines, which were by far the most numerous, was a different period in the natural history of the pandemic than when we started administering Moderna. So it is important to recognize that it was not a prospectively controlled randomized trial of different vaccines; it was an observational study of pretty much a whole country and how it responded to the implementation of those different vaccines, which were all given to different people at different times of the pandemic. And of course, different times of the pandemic means that many different people will have already had a COVID infection and then gone on to have a booster or third vaccination. So, if you like, the immunological landscape in which these different vaccines were given in this very large population will have been different. Dr. Greg Hundley: Right. So I understand there are differences in timing, great point, but did you see any differences in the occurrence of myocarditis relative to either of the mRNA vaccines versus the adenovirus vaccine? Dr. Keith Channon: Yeah, we did. What we found is that, interestingly, there did appear to be a higher likelihood of being diagnosed with myocarditis in the 28 days after the mRNA-1273 vaccine, Moderna vaccine, and that was particularly, as I've already said, in men younger than the age of 40 years. I should say again, of course, that vaccine was given to the smallest number of people in the UK and it also tended to be rolled out later, so it was the second or third dose of the vaccine where that signal was most seen. But again, the second and third dose was by definition typically the booster vaccine later on in the pandemic. But that's what we found. We did find these interesting differences. The incidence of myocarditis was increased after all of the vaccine doses compared with the period when people had not received a vaccine, but this was a very modest increase for most of the vaccines; but for the mRNA vaccines, particularly Moderna, it seemed to be more strikingly increased in the 28 days after the second or third dose of the vaccine. So I guess the message from that result is that there do seem to be these intriguing differences, both in the response to different COVID vaccines, either viral or mRNA or indeed even different types of mRNA vaccine, and possibly after the different dose of vaccines. In other words, after second or third sequential doses. Dr. Greg Hundley: And Keith, you mentioned a few minutes ago that you also had an opportunity to examine situations where maybe a patient had a vaccine and then subsequently contracted COVID, or vice versa, maybe they had had COVID and then later on had a vaccine, did you find any differences in the incidence of myocarditis in those situations as opposed to, perhaps, patients that really never had a documented episode of a COVID infection and then always had received the two vaccines and the booster dose? Dr. Keith Channon: Yeah, that's a harder question and is less powerfully addressed by our study, even though we were able to temporally control for that. Previous COVID infection did not preclude the risk of myocarditis after subsequent vaccine doses, but it wasn't a big enough signal to be able to give much detail over the relative risk between... Because if you think of the permutations of COVID infection plus or minus three vaccines, there's a lot of different sequential steps there, but having had COVID first doesn't prevent this small but significant signal; having a vaccine before you then get COVID infection does reduce your risk of myocarditis along with pretty much all other COVID complications. So I think that's a really important public health message here and indeed the overarching finding of our study, which you could argue is the least exciting one but perhaps the most important, which is that you have a higher likelihood of suffering with myocarditis after COVID infection compared with after a COVID vaccination. And if you have COVID vaccination, in general, your risk of myocarditis is lower, obviously your risk of COVID infection is lower, and your risk of getting myocarditis after that COVID infection, should you still get one is also lower. So I think these are very intriguing, interesting findings that might make us think about mechanism and vaccine policy, but ultimately there are very strong endorsement of getting vaccinated to prevent the consequences of COVID-19. Dr. Greg Hundley: Excellent point. And then, Keith, just quickly, next study that maybe your group is considering in this space with this large database? Dr. Keith Channon: Yes. Well, I think there are two aspects to the study. Our group, which, as I've said, focuses mainly on large epidemiological data sets, having established this infrastructure in the UK led by universities like Oxford and Edinburgh and funded by the British Heart Foundation and others, means that we now have this infrastructure. So the surveillance and the data collection and the analysis is ongoing and we'll be able to add more cases and more power and more data, and there will be other studies that we can look at. Second, I think there are some really quite interesting mechanistic studies that could be done based on these provocative findings to try to understand which different types of vaccines and, indeed, the immune responses which those vaccines generate. How are they linked to myocarditis and, indeed, to other cardiac and even other organ complications from COVID-19? And there are ongoing studies in the UK and elsewhere in the world that are very much focused on looking at the organ-specific consequences of COVID infection in patients who've been vaccinated or not. For example, using detailed cardiac MRI to look at the heart and look for subclinical myocarditis and to correlate any evidence of subclinical myocarditis with the immune signature, both the antibody and the cellular immune response, in the blood from those patients. So I think what we're going to see here are enormous epidemiological studies with n=43 million, and we're also going to see more mechanistic experimental medicine immunology studies to try and tease out mechanism, and I think to understand two things. One is how to protect ourselves best against COVID-19, and what are the best vaccines and how best to use them. And second, if we can learn something about the mechanisms of myocarditis along the way, that's a really useful bonus that's come out of this pandemic. Dr. Greg Hundley: Very nice. Well, listeners, we want to thank Dr. Keith Channon for bringing us this very interesting article from Great Britain highlighting that, overall, the risk of myocarditis is greater following SARS-CoV-2 infection as opposed to a COVID-19 vaccination, and even really remains modest following sequential doses, including the booster dose of some of the mRNA vaccines. Well, on behalf of Carolyn and myself, we want to wish you a great week and we will catch you next week on the run. This program is a copyright of the American Heart Association 2022. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit AHAjournals.org.

L'entreprise américaine de biotechnologies Moderna va construire au Royaume-Uni un centre de recherche et de production consacré aux vaccins ARN messager, a annoncé mercredi 22 juin le gouvernement britannique, soulignant vouloir se préparer «aux futures pandémies». Ce contrat, dont les termes financiers n'ont pas été communiqués, visent à donner accès aux patients du service public de santé britannique «à la prochaine génération de vaccins et traitements», a indiqué le ministère de la Santé dans un communiqué. Il prévoit un centre de recherche et développement sur les vaccins ARN, un centre de production de vaccins, et la tenue d'une importante part des essais cliniques sur le sol britannique. Le gouvernement souligne le rôle «pivot» de cette technologie dans la lutte contre la pandémie, et son «potentiel pour permettre des percées concernant certains types de maladies comme le cancer, la grippe, la démence ou les maladies cardiaques». La construction doit commencer dès cette année pour de premiers vaccins produits en 2025. «Le centre pourra augmenter rapidement sa production en cas d'urgence sanitaire, renforçant la capacité du Royaume-Uni à répondre aux futures pandémies», est-il précisé. «Notre investissement va garantir des vaccins contre les virus les plus dangereux, nous plaçant au premier rang des batailles contre les menaces futures», a insisté le premier ministre Boris Johnson, cité dans le communiqué. Le Royaume-Uni, l'un des pays les plus touchés par la pandémie de Covid-19 avec près de 180.000 morts, a acheté des vaccins en masse ces dernières années, notamment de technologies ARN achetées à Pfizer et Moderna, tandis qu'il produisait surtout des sérums plus classiques AstraZeneca/Oxford. --- Send in a voice message: https://anchor.fm/aziz-mustaphi/message

Large study links higher nutrient intake with lower risk of mortality during 9.3-year median period   University of Connecticut, January 25, 2022   A study that utilized data from the National Health and Nutrition Education Survey (NHANES) found an association between having an adequate intake of vitamin E, iron, magnesium, potassium, EPA and DHA, essential amino acids and fiber and a lower risk of dying during a median follow-up period of 9.3 years. The study included 20,602 men and women enrolled in NHANES. During a median 9.3-year period, 3,539 participants died.  The participants who survived were more likely to have reported a higher intake of specific nutrients. Notably, compared to participants whose magnesium intake was among the lowest one-third, those whose intake was among the top third had a 22% lower adjusted risk of dying from any cause, a 35% lower risk of dying from cardiovascular disease and a 29% lower risk of cancer death during follow-up. Magnesium wasn't the only nutrient linked to a lower risk of mortality during follow-up; the top consumers of vitamin E, iron, potassium and fiber had 19%, 15%, 18% and 16% lower respective risks of premature all-cause mortality.   (NEXT)   Active ingredient in cannabis protects aging brain cells   Salk researchers find cannabinol preserves mitochondrial function and prevents oxidative damage to cells Salk Institute, January 25, 2021   Decades of research on medical cannabis has focused on the compounds THC and CBD in clinical applications. But less is known about the therapeutic properties of cannabinol (CBN). Now, a new study by Salk scientists shows how CBN can protect nerve cells from oxidative damage, a major pathway to cell death. The findings, published online January 6, 2022, in the journal Free Radical Biology and Medicine, suggest CBN has the potential for treating age-related neurodegenerative diseases, like Alzheimer's. “We've found that cannabinol protects neurons from oxidative stress and cell death, two of the major contributors to Alzheimer's,” says senior author Pamela Maher, a research professor and head of Salk's Cellular Neurobiology Laboratory. “This discovery could one day lead to the development of new therapeutics for treating this disease and other neurodegenerative disorders, like Parkinson's disease.”   (NEXT)   Apple polyphenols may slash inflammation marker levels, change gut microbiota   University of Auckland (New Zealand)   Polyphenols from apples may modify the bacterial populations in the gut, and reduce markers of inflammation, according a new study from New Zealand Data from a study indicated that adding extracts from genetically engineered apples with increased flavonoids led to 10-fold decrease in levels of pro-inflammatory prostaglandins than extracts from non-transformed apples. In addition, the total number of bacteria in the colons of animals fed a diet containing the transformed apple extracts was 6% higher than for mice fed the control diet, said the researchers in the Journal of Nutrition . “The findings here further demonstrate that apple consumption affects aspects of inflammatory pathways and the gut microbiota.   (NEXT)   Extra 10 minutes of daily activity could save 110,000 U.S. lives annually   National Cancer Institute, January 25, 2022   If everyone between 40 and 85 years of age were active just 10 minutes more a day, it could save more than 110,000 U.S. lives a year, a large study reports. "Our projections are based on an additional 10 minutes of moderate to vigorous physical activity," said lead researcher Pedro Saint-Maurice at the U.S. National Cancer Institute in Bethesda, Md. "If the walk is brisk, it counts." And added exercise benefits everyone—white, Black, Asian and Hispanic, men and women, the investigators found.   (NEXT)   Alzheimer's defense: omega-3s linked to larger brain volume   University of South Dakota, January 24, 2022   Among the myriad changes that accompany aging, shrinking brain volume can be a worrying one. A normal part of growing older, it can also be a sign of Alzheimer's disease. But the good news is that a recent study suggests people with higher levels of omega-3 fatty acids have larger brain volumes in old age. The research, published in Neurology, the medical journal of the American Academy of Neurology, suggests that the larger brain volumes associated with higher omega-3 levels are the equivalent to preserving up to 2 years of brain health.   (VIDEO)   Dr. Robert Malone | Senator Ron Johnson COVID-19: A Second Opinion   (OTHER NEWS)   Authoritarian Madness: The Slippery Slope from Lockdowns to Concentration Camps   By John W. Whitehead & Nisha Whitehead, January 26, 2022   In the politically charged, polarizing tug-of-war that is the debate over COVID-19, we find ourselves buffeted by fear over a viral pandemic that continues to wreak havoc with lives and the economy, threats of vaccine mandates and financial penalties for noncompliance, and discord over how to legislate the public good without sacrificing individual liberty. The discord is getting more discordant by the day. Just recently, for instance, the Salt Lake Tribune Editorial Board suggested that government officials should mandate mass vaccinations and deploy the National Guard “to ensure that people without proof of vaccination would not be allowed, well, anywhere.” In other words, lock up the unvaccinated and use the military to determine who gets to be “free.” In Italy, the unvaccinated are banned from restaurants, bars and public transportation, and could face suspensions from work and monthly fines. Similarly, France will ban the unvaccinated from most public venues. In Austria, anyone who has not complied with the vaccine mandate could face fines up to $4100. Police will be authorized to carry out routine checks and demand proof of vaccination, with penalties of as much as $685 for failure to do so. In China, which has adopted a zero tolerance, “zero COVID” strategy, whole cities—some with populations in the tens of millions—are being forced into home lockdowns for weeks on end, resulting in mass shortages of food and household supplies. Reports have surfaced of residents “trading cigarettes for cabbage, dishwashing liquid for apples and sanitary pads for a small pile of vegetables. One resident traded a Nintendo Switch console for a packet of instant noodles and two steamed buns.” For those unfortunate enough to contract COVID-19, China has constructed “quarantine camps” throughout the country: massive complexes boasting thousands of small, metal boxes containing little more than a bed and a toilet. Detainees—including children, pregnant women and the elderly— were reportedly ordered to leave their homes in the middle of the night, transported to the quarantine camps in buses and held in isolation. If this last scenario sounds chillingly familiar, it should. Eighty years ago, another authoritarian regime established more than 44,000 quarantine camps for those perceived as “enemies of the state”: racially inferior, politically unacceptable or simply noncompliant. While the majority of those imprisoned in the Nazi concentration camps, forced labor camps, incarceration sites and ghettos were Jews, there were also Polish nationals, gypsies, Russians, political dissidents, resistance fighters, Jehovah's Witnesses, and homosexuals. You don't have to be unvaccinated or a conspiracy theorist or even anti-government to be worried about what lies ahead. You just have to recognize the truth in the warning: power corrupts, and absolute power corrupts absolutely. This is not about COVID-19. Nor is it about politics, populist movements, or any particular country. This is about what happens when good, generally decent people—distracted by manufactured crises, polarizing politics, and fighting that divides the populace into warring “us vs. them” camps—fail to take note of the looming danger that threatens to wipe freedom from the map and place us all in chains. It's about what happens when any government is empowered to adopt a comply-or-suffer-the-consequences mindset that is enforced through mandates, lockdowns, penalties, detention centers, martial law, and a disregard for the rights of the individual.   (NEXT)   95% Deceptive: COVID Vaccine Efficacy & Medical Betrayal   How statistical sleights of hand betrayed the heart and soul of medicine. Dr. Benjamin Kaplan-Singer, MD.   January 25, 2022   COVID Combat Zones We are in the midst of informational and narrative warfare. All things COVID are active combat zones. Within this, vaccines are the most polarizing, controversial, hot button issue. On one extreme are those who believe COVID vaccines should be mandatory whether that is accomplished by: applying censorship, public shaming, and cancel culture to stifle dissent; making employment, school enrollment, travel, and private/public event participation contingent on vaccination status; threatening to remove licenses from medical professionals; or even going door-to-door with armed enforcers. (Yes, I have heard this suggested on multiple occasions.) On the other extreme are those who believe COVID vaccines are a bioweapon being used for depopulation, soul-harvesting, and to socially engineer a technocratic, totalitarian, panopticon state. Most people are in the center, doing their best to make sense of the risks and benefits of vaccination and early treatment options in order to make informed choices for themselves and their families. On November 16, 2020 NIH announced “Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine” reporting “the candidate was safe and well-tolerated and noted a vaccine efficacy rate of 94.5%.”1 The New England Journal of Medicine published the trial on February 4, 2021 where it reported “94.1% efficacy.”2 On December 10, 2020 Pfizer and BioNTech announced “Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine,” reporting “the vaccine candidate was well tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection 7 days or more after the second dose.”3  The New England Journal of Medicine published the trial on December 31, 2020 reporting the vaccine was “95% effective in preventing Covid-19.”4 From “95% effective” it is a short cognitive leap to: When X% of the population vaccinates, COVID will (mostly) disappear When COVID (mostly) disappears life will return to normal(-ish) Vaccination protects the vulnerable People have a social responsibility to vaccinate The social contract means to participate in society you must vaccinate Trials showed the vaccines are safe, therefore the vaccines are safe The benefits of the vaccines clearly outweigh the risks The unvaccinated are overburdening hospitals If you do not vaccinate you are overburdening hospitals Overburdening hospitals kills innocent people The unvaccinated are the ones spreading COVID If you do not vaccinate you are killing someone's grandma or immunocompromised child Trust the science, trust the experts The unvaccinated are spreading misinformation The unvaccinated are anti-science, brainwashed, delusional conspiracy theorists, ignorant, selfish assh*les Anyone who questions vaccines should be shamed, censored, canceled, or penalized Relative Deception The “95% effective” frame comes from Pfizer-BioNTech's published trial and refers to a specific statistical measurement called relative risk reduction Of note, the trials did not look at: the effectiveness of the vaccine on hospitalizations, deaths, or transmission; on the effect of confirmed cases of COVID beyond 2 months post-vaccination; safety beyond 2 months; in addition, the control group did receive vaccination in what is called “crossover” which makes medium and longer term safety data very difficult, if not impossible, to ascertain. Furthermore, for trial results to translate to real world conditions we must make at least two assumptions: that the population being vaccinated is comparable to the population in the study and that the virus does not evolve in a way that reduces vaccine effectiveness. Keep in mind, the absolute risk reduction from these trials refers to the average decreased risk an individual has of getting a confirmed case of COVID (i.e. it does not confer information about hospitalization, death, transmission, nor “long COVID”) within a certain time window after vaccination. Absolute risk reduction is the best available measurement, but only conveys the average reduction in risk for the average individual in the trial. Pfizer-BioNTech's “95% effective” vaccine reduces risk on average by 0.84% Moderna-NIH's “94% effective” vaccine reduces risk on average by by 1.2% Gamaleya's “91% effective” vaccine reduces risk on average by 0.93% J&J's “67% effective” vaccine reduces risk on average by 1.2% AstraZeneca–Oxford's “67% effective” vaccine reduces risk on average by 1.3% As you can clearly see, there is no correlation between the espoused effectiveness of a vaccine based on its relative risk reduction, and how much the vaccine decreases your personal risk of a confirmed case of COVID based on absolute risk reduction. Given the COVID vaccines reduce an individual's risk of a confirmed case within a certain time window after vaccination by 0.84-1.3% – which some people will consider a marginal benefit – obvious questions ensue.

Há exatamente um ano, o Reino Unido inaugurava a campanha de vacinação contra a Covid-19. Tinha início, em todo o planeta, uma corrida contra o tempo para reduzir o número de casos graves e mortes e aliviar as medidas de restrição, que mergulharam a economia mundial em recessão. Taíssa Stivanin, da RFI Os britânicos utilizaram principalmente o imunizante desenvolvido pelo laboratório AstraZeneca em parceria com a Oxford, uma das vinte vacinas que ainda são aplicadas no mundo, e desenvolvida em cerca de um ano – o vírus, como se sabe, foi descoberto em 2019 em Wuhan, na China. A tecnologia usada pela AstraZeneca/Oxford é a do adenovírus – um vírus de resfriado enfraquecido, retirado de um chimpanzé, que em seguida é modificado geneticamente. Esse vetor viral carrega o material genético da proteína Spike, que o coronavírus utiliza para entrar nas células humanas, fazendo com o que o organismo produza anticorpos contra o SARS-CoV-2. Mas a verdadeira revolução na história dessa campanha inédita foi o aparecimento das vacinas que utilizam o RNA mensageiro. No início, os imunizantes foram vistos com receio por parte da população, reticente a injetar uma tecnologia considerada nova, mas que, na realidade, já vinha sendo estudada desde 1998. Foi nessa época que o imunologista suíço Steve Pascolo iniciou pesquisas sobre o uso da técnica em vacinas destinadas a tratar pacientes com câncer, na universidade de Tubingen, na Alemanha, e na empresa de biotecnologia CureVac, nos anos 2000, da qual ele é co-fundador. O grande desafio era preservar as características da molécula de RNA, que se degrada rapidamente. “Uma das principais linhas de pesquisa dos últimos anos foi em relação à concepção da 'embalagem', a cápsula que envolveria essa cópia de molécula de RNA mensageiro, que é muito instável fora das células. Além disso, essa cápsula deveria se autodestruir no momento certo, para que o RNA pudesse agir dentro da célula”, explicou o pesquisador em entrevista à RFI. “Por isso, uma grande parte da evolução do RNA mensageiro, nos últimos anos, esteve relacionada a esse invólucro que o protege, chamado de lipossomo ou nanopartícula. O desafio, mais uma vez, foi achar lipossomos e nanopartículas capazes de encapsular o RNA, para protegê-lo e possibilitar sua penetração na célula”, completa. Vacina da Pfizer foi lançada em um ano O RNA mensageiro também interessou um casal de pesquisadores: os hoje célebres Ugur Sahin e Ozlem Tureci, que criaram a empresa de biotecnologia BioNTech em 2008 para, como Steve Pascolo, testar a vacina contra o câncer. Ugur é de origem turca. Ele chegou quando ainda era criança na Alemanha e se tornou imunologista. Tureci nasceu no país e é filha de um cirurgião. Os dois se encontraram no hospital onde trabalhavam e criaram a primeira empresa, juntos, em 2001. Quando o novo coronavírus foi identificado em Wuhan e os pesquisadores tiveram acesso aos primeiros dados sobre o o vírus e o perigo que ele representava, ao provocar pneumonias que levavam a uma grave insuficiência respiratória, o imunologista da BioNTech decidiu colocar seus 1.500 assalariados para trabalhar em uma vacina que utilizasse o RNA mensageiro contra o coronavírus, após a assinatura de um contrato com a gigante farmacêutica Pfizer. Em menos de um ano, o laboratório lançou a vacina no mercado. O imunizante age enviando instruções para o sistema imunológico combater o SARS-CoV-2. Paralelamente, a empresa Moderna, criada em 2010 nos Estados, também desenvolveu uma vacina similar altamente eficaz, mais dosada em RNA mensageiro, mas que, devido ao preço elevado, acabou se popularizando menos do que a vacina da Pfizer, administrada em bilhões de pessoas em todo o mundo. Após o Reino Unido dar a largada em dezembro de 2020, vários países começaram a vacinar seus cidadãos no mesmo mês, a maioria com a vacina de RNA mensageiro do laboratório Pfizer/BioNTech: Estados Unidos, Canadá e Emirados Árabes Unidos, em 14 de dezembro; Arábia Saudita no dia 17; Israel no dia 19; e a União Europeia no dia 27. Na França, a primeira vacinada, em 27 de dezembro, foi Mauricette, 78 anos, residente em uma casa de repouso medicalizada para idosos, na região parisiense. Desde então, mais metade da população mundial recebeu ao menos uma dose da vacina, o equivalente a 4,3 bilhões de pessoas, e 44% estão com o esquema vacinal completo. No total, 8,1 bilhões de doses foram aplicadas no mundo. Além da AstraZeneca e Pfizer, as outras vacinas mais usadas são as desenvolvidas pelos laboratórios americanos Johnson & Johnson e Moderna, as chinesas Sinopharm e Sinovac e a russa Sputnik V. Desigualdade no acesso Com a chegada da ômicron, variante surgida em novembro na África do Sul, um dos países com a mais baixa taxa de vacinação do mundo, a questão da desigualdade do acesso à vacina se tornou essencial. Nos países mais pobres, o ritmo mais lento contribui para ao aparecimento de novas cepas, que encontram um terreno fértil em um nicho não vacinado. O mecanismo Covax, liderado pela Organização Mundial da Saúde (OMS) para garantir acesso igualitário às vacinas, entregou a primeira remessa no fim de fevereiro em Gana. Até agora, o Covax distribuiu apenas 591 milhões de doses a 144 países ou territórios, muito abaixo da meta de 2 bilhões estabelecida para 2021. Para especialistas como a infectologista e professora da Universidade Federal de Goiás Cristiana Toscano, única brasileira e sul-americana no Grupo Estratégico Internacional de Experts em Vacinas (Sage) da OMS, o Covax não basta para assegurar uma distribuição mais justa dos imunizantes. “A ciência cumpriu seu papel, temos muitas vacinas desenvolvidas e disponibilizadas e em desenvolvimento”, disse. “Mas acho que a humanidade está falhando, principalmente os políticos dos vários países e a articulação global nesse sentido, para de fato garantir o acesso igualitário e que as pessoas do mundo todo consigam ser vacinadas”, disse em entrevista à RFI em fevereiro deste ano. Desde junho de 2021, praticamente todos os países estão aplicando as vacinas, mas o ritmo ainda é lento e faltam doses. De acordo com uma classificação do Banco Mundial, a média mundial é de 104 para cada 100 habitantes. Nos países de alta renda, essa média chega a 149 para 100. A África, onde surgiu a ômicron, é o continente menos protegido, com 18 doses para cada 100 habitantes. Burundi e República Democrática do Congo são os países menos vacinados, com 0,007% e 0,06% da população respectivamente. Terceira dose e vacina para crianças Com a descoberta de que a proteção das vacinas diminui com o tempo, a administração de uma terceira dose busca manter a proteção da população e também reforçar a taxa de anticorpos diante da chegada da ômicron, que pode ser menos sensível aos imunizantes. A abertura da vacinação paras crianças de 5 a 11 anos, que começou em poucos países, também poderá mudar o curso da epidemia. A imunização nessa faixa etária causa polêmica, mas é fundamental para o controle da epidemia, como explicou à RFI o pediatra americano Willie Ng. Ele tem mais de 40 anos de experiência e atua em uma clínica de Cincinatti, em Ohio. “Sou a favor da vacina para todas as crianças, até as mais jovens. Há muitos pais que acham que como os casos são leves na maioria, é melhor adquirir a imunidade natural. Acho que sempre há o risco de se ter um caso mais severo, ou desenvolver a Covid-19 longa. Nunca se sabe, sempre é melhor prevenir”, afirma.

No Roda Viva, a jornalista Vera Magalhães recebe a médica brasileira Sue Ann Costa Clemens. Chefe do Comitê Científico da Fundação Bill e Melinda Gates, Sue Ann é professora em Oxford e coordenou os testes do imunizante da AstraZeneca/Oxford no Brasil. Atualmente, realiza estudos sobre a aplicação das doses de reforço contra o coronavírus. A médica também faz parte dos grupos de estudos responsáveis pelo Covax, o consórcio internacional criado pela Organização Mundial de Saúde para aquisição e distribuição de vacinas aos países mais pobres. Sue Ann está lançando o livro História de uma Vacina, onde relata os desafios enfrentados para trazer os primeiros testes clínicos da vacina para o Brasil. #RodaViva

O Ministério da Saúde recebe unidades da Astrazeneca/Oxford na quarta-feira (21).

***) No Rio de Janeiro, gestantes que receberam a primeira dose da vacina AstraZeneca/Oxford poderão tomar a segunda dose com outro imunizante. No caso, o desenvolvido pela Pfizer/BioNTech. A autorização foi dada com base nas recomendações do comitê científico da Secretaria Municipal de Saúde do Rio de Janeiro, e foi divulgada na terça-feira (29), pelo secretário de Saúde, Daniel Soranz, em seu perfil no Twitter. O que se sabe sobre os efeitos positivos e, eventualmente, negativos desta estratégia? É sobre isso que fala este episódio do podcast 15 Minutos. A convidada é a Amanda Milléo, repórter especialista em Saúde da Gazeta do Povo.***Ficha técnica: ‘15 minutos', podcast de notícias da Gazeta do Povo #Apresentação e roteiro: Márcio Miranda; direção de conteúdo: Rodrigo Fernandes; equipe de produção: Maria Eduarda Scroccaro montagem: Leonardo Bechtloff; estratégia de distribuição: Marcus Ayres.

The Delta variant of coronavirus has been detected in 92 countries, leading to lockdowns and the reintroduction of limitations on border crossing. Additionally, researchers in India have identified a variant of the Delta variant they're calling Delta Plus, though it's so far unknown whether it's any more transmissible than the original variant. Mixing and matching the Pfizer-BioNTech and AstraZeneca-Oxford vaccines may increase immunity, according to early results from a study in the UK. If the CDC approves combining vaccine brands, it could increase access to the vaccine and avoid supply bottlenecks. And in headlines: Ethiopia declares ceasefire in Tigray, airstrikes and rocket attacks between U.S. forces and Iranian-backed militants, and SCOTUS upholds transgender bathroom rights. Show Notes: NIH clinical trial evaluating mixed COVID-19 vaccine schedules – https://bit.ly/3jot1FZ For a transcript of this episode, please visit crooked.com/whataday. Learn more about your ad choices. Visit podcastchoices.com/adchoices

O ministério da saúde teria pago valor quatro vezes mais caro em doses de vacinas do laboratório indiano Bharat Biotech em comparação ao que despendido na aquisição do imunizante da AstraZeneca/Oxford. A compra foi feita por meio da empresa brasileira Precisa Medicamentos. Inclusive paira suspeita sobre os representantes porque o preço na farmacêutica seria de pouco mais de um dólar (US$ 1,34), o que colocaria a dose como uma das mais baratas. Também nesta edição o relatório da Agência Brasileira de Inteligência – ABIN sobre o capital de Luciano Hang; o FMI defendendo mais impostos e tributação a ricos latino-americanos; e a história do anúncio de vaga de emprego em Campinas que procura governanta vacinada com a Pfizer. De segunda a quinta, sempre na faixa das 21h, o #JCInforma​​ é o seu ponto de encontro com os cronistas do JC e as principais manchetes do dia. Neste espaço, os destaques dão o tom da conversa comandada pelo cronista Pedro Araujo, editor de Política no Recife, com a participação, em rodízio diário, de Claudio Porto e Adriano Garcia, ambos editores de Política em São Paulo, Arthur Luiz, editor no Rio de Janeiro, e Ulisses Santos, editor no Rio Grande do Sul.

Neredeyse bir buçuk yıldır pandemi ile yaşıyoruz. Rutin hayatımızda dahil birçok değişiklik oldu. Ne zaman normale döneceğiz? Bu aşamalar nasıl olacak? Maskelerden ne zaman kurtulacak, rahat rahat ne zaman gezmeye başlayacağız gibi aklımızda bir sürü soru var. Aşılanma oranlarının artmasıyla bu sürece geçişimiz hızlanacak gibi duruyor. Amerika'da Centers for Disease Control and Prevention'ın (CDC) yayınladığı “When You've Been Fully Vaccinated” adlı yazıdan bahsederek olası süreçlerden bahsetmek istiyorum. Keyifli okumalar. Güncel veriler doğrultusunda Covid-19 aşıları yüksek oranda Covid-19 hastalığına yakalanmaktan korumaktadır. Aşıya rağmen yine de hasta olunursa da hasta olan kişilerde ağır hastalık görülme ihtimali düşmekte ve ve komplikasyon riski azalmaktadır. Ayrıca bu kişilerin Covid-19 bulaştırıcılığını azaltmaktadır. Covid-19 aşı dozları tam olan kişiler için CDC önerilerde bulunurken mevcut verilerden ve devam etmekte olan çalışmalardan yararlanılmış​1–4​. CDC'nin tam aşılı olarak kabul ettiği popülasyonun tanımı ile başlayacak olursak Amerika'da hali hazırda kullanılan ve FDA onaylı aşılar dikkate alınmış. Kişiler, çift doz olarak yapılan aşılar ( Pfizer veya Moderna) için ikinci dozdan, tek doz yapılan aşılar (Johnson & Johnson's Janssen) için de aşıdan 2 hafta sonra tam aşılı olarak kabul edilmekteler. Bağışıklık sistemini güçsüzleştiren hastalığı olan ya da buna neden olan ilaçları kullanan kişileri bu kapsamın dışında bırakmışlar ve kişisel hekimlerinin önerileri doğrultusunda gerekli önlemleri almaları önerilmiş. Yazının temelinde kapalı alan ve açık alanlardaki güvenli aktivitelerden bahsedilmiş ve bu aktiviteler aşılı ve aşısız insanlar için risklendirilmiş. Açık Alan Aktiviteleri Kapalı Alan Aktiviteleri Tam aşılı insanlar için yukarıdaki güvenli aktivitelere ilaveten; -ABD içindeki yolculuklar için önce ve sonra testleri kaldırılmış, yolculuk sonrası karantinaya gerek duyulmadığı söylenmekte. -ABD dışına uçuşlar için uçuş öncesi test istenmemesine rağmen dönüş uçuşları için hala test istenmeye devam edilmekte. Hatta dönüş uçuşundan 3-5 gün sonra tekrar test istenilmekte. -Covid-19'lu biriyle temas halinde izolasyon ya da test istenmemekte (Evsiz barınakları, hapishaneler gibi toplu yerlerde çalışanlar hariç tutulmuş). Bu özgürleşme önerileri verilirken bir yandan da hala dikkat edilmesi gereken aktiviteler vurgulanmış; -İş yerleri ve yerel işletmelerin kurallarına uyulmasına devam edilmesi -Toplu taşıma (uçak, otobüs, tren) kullanırken kendini ve etrafındakileri korumak için korunma önlemlerine dikkat edilmesi gerektiği özellikle maske takılması gerektiği vurgulanmış. -Kişilerin kendi sağlıklarını yakından izlemeleri gerektiği, Covid-19 semptomları açısından dikkatli olmaları ve semptomatik olunması halinde izolasyon önerilerine dikkat edilmesi ve test verilmesi önerilmiş. Bu süreç içerisinde ise hala cevabı bilinmeyen soruların olduğu ve öğrenilmeye devam edilen noktalar da belirtilmiş. Aşının virüsün varyant formlarına karşı ne kadar etkili olacağı konusunda hala bir çok soru işareti bulunmakta. Aşıların immün süprese insanlarda ne kadar koruyucu olacakları henüz bilinmiyor ve aşının koruyuculuğunun ne kadar süre devam edeceği de bir diğer bilinmeyen nokta. Bu konularda da yeni bilgiler edinildikçe yeni güncellemeler gelecektir. Yazının sonuna iliştirilen şu küçük not dikkat çekmekte. Bu rehberin FDA onaylı aşılar için yazıldığı ama Dünya Sağlık Örgütü'nün onayladığı aşılar (AstraZeneca/Oxford vs.) için de kullanılabileceği belirtilmiş. Güncel verilere bakacak olursak 30 Mayıs 2021 itibariyle, ABD'de 366.316.945 ve Türkiye'de 29.000.857 aşı yapılmış durumda ve oranları şöyle; ABD'de Aşılanma Verileri Aşılı İnsanlarTek Doz AşılanmaTam AşılanmaToplam167.733.972135.087.319Toplam Nüfusa Yüzdesi%50,5%40,712 Yaş Üstü Aşılanmış Kişiler167.605.730135.078.53712 Yaş Üstü Aşılanma Yüzdesi%59,8%48,218 Yaş Üstü Aşılanmış Kişiler161.535.

A Fiocruz assinou um contrato de transferência de tecnologia que permite a produção, no Brasil, do insumo farmacêutico ativo (IFA) usado na fabricação da vacina AstraZeneca/Oxford contra a Covid-19. A medida deve facilitar a produção da vacina no país. A segunda dose do imunizante foi aplicada em pouco mais de 22 milhões e 300 mil brasileiros, 13,9% da população.

The Bill Kelly Show Podcast: The Ontario government will replace Dr. David Williams as chief medical officer of health in June, the province's health minister announced on Sunday. Williams is set to retire on June 25, Christine Elliott said in a news release. He will be replaced by Dr. Kieran Moore,  currently the medical officer of health for Kingston, Frontenac and Lennox & Addington Public Health. Moore is expected to step into the role on June 26. Williams, who was set to retire months ago but delayed the move because of the COVID-19 pandemic, has held the position for five years. Premier Doug Ford's government will table a motion in the legislature on Monday to formalize the appointment, according to the news release. Moore is expected to work with Williams as he gets used to the job, starting June 7. GUEST: Richard Brennan, Former Journalist with The Toronto Star covering Queen's Park and Parliament Hill - Ontario's science table says schools can safely reopen on regional basis What are the risks of extending the expiry date for the AstraZeneca-Oxford vaccine? GUEST: Dr. Peter Juni, Director of Ontario's Science Table and a Professor of Medicine and Epidemiology at the University of Toronto - The pandemic's impact on the economy has been staggering — and complicated. Some of the typical measurements are in conflict: the stock market is soaring while 1.5 million Canadians are out of work. Many of the largest companies recorded historic profits while one quarter of small businesses reported revenue drops of 30 per cent or more. Gross Domestic Product (GDP) contracted in the past year, though the Bank of Canada projects a promising return to pre-pandemic growth. The federal government poured huge sums of money into stimulus measures, but Finance Minister Chrystia Freeland says an economic rebound will help cover the debt. If economists agree on one thing, it is that the price of the pandemic is unprecedented — in dollars, in labour, in product, in everything. But how much, exactly? With expert guidance, we tried to assign a price tag to the pandemic so far. GUEST: Moshe Lander, Senior Economics Lecturer with Concordia University

Argentina superó este martes los 75.000 muertos por covid-19 mientras cumple desde el sábado un confinamiento por nueve días para frenar los contagios, que lo ubican entre los países de mayor índice por millón de habitantes en la región. En Argentina, la imagen de una joven enferma de Covid, tumbada en el suelo de un hospital de Santa Fe esperando una cama, conmocionó al país. La mujer de 22 años, que tenía diabetes, tuvo luego una cama y fue atendida pero falleció. Muchas historias como éstas se viven en este momento en los hospitales argentinos que enfrentan el peor momento de la epidemia de coronavirus. “No ocurre todo el tiempo, pero sí está sucediendo en todas las ciudades, a lo largo y ancho de todo el país”, dice a RFI la médica integrante de la Sociedad Argentina de Infectología, Elena Obieta. “Gente que espera para poder ser asistida, que espera poder tener una cama, que espera poder llegar a la terapia intensiva. Y probablemente cuando lo logra ya es tarde”. El país tiene más de 3,6 millones casos positivos de coronavirus, y más de 75.000 muertes por Covid-19, según cifras del Ministerio de Salud. Argentina atraviesa desde hace semanas un aumento de casos y de muertes diarias. Según el último reporte oficial la ocupación de unidades de terapia intensiva a nivel nacional alcanzó el 74,1%, incluyendo tanto el sector público como el privado. La proporción se eleva a 75,2% en las terapias intensivas de la capital y su periferia, donde habitan unos 13 millones de personas. “Estamos en una situación mucho peor que la primera ola”, dice Obieta. “En este momento hay ciudades grandes como Rosario [300 km al norte de Buenos Aires], por ejemplo, o ciudades en Neuquén o Bariloche [ambas en Patagonia, sur del país] que no tienen camas disponibles en la terapia intensiva. Y no es solamente la disponibilidad de una cama, es [también la disponibilidad de] un respirador, un médico terapista, un enfermero, un kinesiólogo que puedan atenderte. ¿Por qué esto sucede? Porque tenemos muchos casos positivos, por día más de 35.000 [casos nuevos]. Y esto con un ritmo de vacunación que aún no ha alcanzado a los que tienen que llegar. Quizá se está vacunando, aunque sea con una dosis, a los demás de 60 años, pero hay una gran cantidad de gente que tiene entre 18 y 59 años, con factores de riesgo, como fue el caso de esta niñita de 22 años. Ella tendría que haber estado vacunada, pero todavía no le había llegado la vacuna”. Argentina recibió el miércoles 26 de mayo 657.600 dosis de la vacuna AstraZeneca proveniente de Amsterdam a través del mecanismo Covax. El mismo día también arribó desde Moscú un nuevo cargamento de 470.035 dosis de la vacuna Sputnik del laboratorio Gamaleya con el cual Argentina superó las 15 millones de dosis recibidas. El pasado lunes el país recibió un embarque con 843.000 vacunas provenientes de Estados Unidos que representan la primera partida de inmunizantes de AstraZeneca-Oxford hechas con principio activo producido en Argentina, de un total de 22,4 millones de compras del país sudamericano. Desde que inició la campaña de vacunación el 29 de diciembre pasado ya han sido aplicadas unos 11,46 millones de dosis por la que fueron inmunizadas 8,9 millones de personas con una dosis y 2,5 millones con el esquema completo de dos aplicaciones. Nuevo confinamiento Ante la grave situación el gobierno decretó un confinamiento con restricción de movilidad de la población durante nueve días, que comenzó el sábado 22 de mayo. Las nuevas restricciones dividen a la sociedad, en un país que comenzaba a tener signos de reactivación luego de tres años de recesión agravados por la pandemia en 2020, año en que el Producto Interno Bruto se derrumbó 9,9%. “Hubo un relajamiento por un cansancio de las medidas de cuidado”, dice Obieta. “No olvidemos que tuvimos la cuarentena más larga del mundo. Entonces la gente se dijo 'Basta. Tengo que salir a trabajar'. En Argentina hay hasta un 40% de empleo informal. Es decir el que no trabaja no come. Todo el relajamiento que vimos en el verano, las fiestas navideñas, el entierro multitudinario de Maradona, mítines políticos, marchas a favor o en contra del aborto, fueron eventos súper diseminadores de esta infección. [A eso] hay que sumar el ingreso de nuevas cepas como la de Manaos, que es más contagiosa. Y ahora viene el frío, entonces la gente se encierra, no ventila las habitaciones y tenemos muchísima más circulación viral y no tenemos vacunación suficiente. Es un cóctel explosivo”. En marzo, la actividad económica argentina registró un aumento de 11,4% respecto a igual mes del año pasado, cuando se inició el largo confinamiento. Así acumuló un crecimiento de 2,4% en el primer trimestre en la comparación interanual, según datos del instituto estatal de estadísticas Indec. La producción industrial, en tanto, creció en marzo 32,8% en la comparación interanual y acumuló en el primer trimestre un aumento de 12,6% respecto de igual lapso del año pasado, de acuerdo al Indec. Con AFP.

Publicado aviso de licitação da Rodoviária de Porto Alegre Rio Grande do Sul recebe nova remessa com 353 mil doses da vacina AstraZeneca/Oxford

Um estudo da agência de saúde pública da Inglaterra diz que as vacinas da Pfizer/BioNTech e de AstraZeneca/Oxford são "altamente efetivas" contra uma das variantes indianas do coronavírus. O monitor Caio Mello (do curso de Jornalismo) apresenta detalhes da pesquisa em questão e algumas das principais conclusões obtidas. Por falar em pandemia, o diretor-geral da Organização Mundial da Saúde (OMS), Tedros Ghebreyesus, criticou, na a Assembleia Mundial da Saúde, a concentração de doses nas mãos de poucas economias e pediu uma mudança imediata de estratégia. Saiba como a OMS pretende reverter a situação.

What should Canada do with the AstraZeneca-Oxford vaccine doses in storage? Hundreds of thousands of Canadians have received one dose, but now several provincial governments have paused offering it as a first dose, due to safety concerns and supply issues. We discuss calls to donate those shots to countries that need them with Lily Caprani, a vaccine advocacy expert with UNICEF global headquarters; Maxwell Smith, a bioethicist at Western University who serves on Ontario's COVID-19 Bioethics Table and Vaccine Distribution Task Force; and Dr. Zain Chagla, an infectious diseases physician at St. Joseph's Healthcare Hamilton.

O Brasil passa por um momento delicado em relação à produção de vacinas. As duas instituições responsáveis por distribuir os imunizantes no País, Butantan e Fiocruz, estão sem insumos para prosseguir com as metas estabelecidas pelo Programa Nacional de Imunização (PNI). A China, que é o produtor do Ingrediente Farmacêutico Ativo (IFA), tem atrasado as entregas do principal componente das vacinas CoronaVac e Astrazeneca/Oxford. Esse desencontro tem sido atribuído aos recentes ataques do presidente Jair Bolsonaro ao país asiático, e a má gestão do ex-ministro das Relações Exteriores, Ernesto Araújo. Com isso, pelo menos 15 estados do Brasil já suspenderam a aplicação da primeira ou da segunda dose dos imunizantes por falta de vacina. O Butantan aguarda a liberação de um lote com 10 mil litros de insumo. Já a Fiocruz anunciou que nos próximos dias 22 e 29 novas remessas do IFA devem chegar ao Brasil. Afinal, há uma crise diplomática entre Brasil e China e, por isso, os insumos não estão sendo liberados? Quais as consequências da paralisação na vacinação do país? No episódio de hoje, vamos conversar sobre esses assuntos com o professor de Direito Internacional e Coordenador do Núcleo de Estudos Brasil-China da FGV Rio, Evandro Menezes, com o pediatra infectologista Renato Kfouri, diretor da Sociedade Brasileira de Imunizações, e com o presidente da Frente Parlamentar Brasil-China, deputado Fausto Pinato (PP-SP). O Estadão Notícias está disponível noSpotify,Deezer,Apple Podcasts,Google Podcasts, ou no agregador de podcasts de sua preferência. Apresentação: Emanuel Bomfim Produção/Edição: Gustavo Lopes e Ana Paula Niederauer Sonorização/Montagem: Moacir Biasi See omnystudio.com/listener for privacy information.

AMONG the headlines for Wednesday, 5 May, 2021, Malaysia’s Phase Three of the National Covid-19 Immunisation Programme (NIP) which was supposed to start in May might be delayed.Coordinating minister Khairy Jamaluddin says this is due to the lack of supplies in the global vaccine distribution chain as pharmaceutical companies seemingly prioritised richer countries which led to slower vaccination rollouts in developing countries.Also, an Alberta woman in her 50s has died from a rare blood clot condition after receiving the AstraZeneca-Oxford vaccine, says the province's chief medical officer of health.In a statement Tuesday, hospital authorities said the woman died of vaccine-induced immune thrombotic thrombocytopenia (VITT). It's Alberta's first death linked to the vaccine in Canada.Listen to the top stories of the day, reporting from Astro AWANI newsroom — all in 3-minutes.We bring you the headlines, weekdays at 5 pm.Stay informed on astroawani.com for these news and more.

Imunizantes da Astrazeneca/Oxford serão distribuídos essa semana para os estados.

The Whole View, Episode 454: J&J and AstraZeneca Covid-19 Vaccines Welcome back to episode 454! (0:28) This is the next part in a series of shows where Sarah and Stacy discuss the science behind the Covid-19 vaccines. They strive to present you with all the information available to make an informed decision about whether receiving the vaccine is right for you. Sarah plans to go through the show with the assumption that listeners have background/base knowledge about vaccines and how they work. So if you have not yet listened to the previous shows in this series, Sarah highly recommends you do before listening to this episode. Previous Covid-19 Shows In episode #440, Sarah and Stacy examined the history of vaccines and the very real statistics on vaccine-induced injury. They also looked at the advances that led to mRNA vaccine technology and the inherent advantages of this platform. Episode #441 explored the safety and efficacy data from the phase 2/3 clinical trials for both the Pfizer/BioNTech and the Moderna covid-19 vaccines. In episodes #443 & #444, Sarah and Stacy answered listener FAQ. This included concerns about adverse events, including autoimmune disease, fertility, and antibody-enhanced infection. They also examined safety concerns for pregnancy and children and addressed common myths circulating on the internet. Stacy and Sarah took a data-driven approach for all four episodes, presenting the science and facts with context, detail, nuance, integrity, compassion, and as objectively as possible. Fact vs. Opinion on The Whole View Stacy underlines that they are not here to convince you of a certain mindset or push a vaccine agenda in this show. Although Stacy and Sarah may share their personal opinions on vaccines, they remind the audience that their opinions are just that - opinions. And what's right for them might not be right for you. They strive to take this same scientific approach today and next week with the J&J and AstraZeneca Covid-19 vaccines. (Yes! You're getting two more vaccine shows!) Stacy also reminds listeners of Sarah's credentials and that she had a Ph.D. in research science. Like the other shows, they will address the rumors, concerns, and myths. It's critical to walk through the facts first. And remember- facts don't have opinions. Stacy and Sarah's primary agenda is to give the data for you to interpret for yourself.   Adenovirus Vector Vaccines J&J and AstraZeneca Covid-19 vaccines are both DNA vaccines that use an adenovirus vector. The concept is similar to the mRNA vaccines but not wholly the same. (5:20) Sarah reminds the audience that to make proteins, DNA is first transcribed into mRNA, which is then translated into protein. So, both J&J and AstraZeneca vaccines deliver instructions to make the full-length covid-19 spike protein. Only slightly different from the instructions for the mRNA vaccines, which have a couple of mutations to stabilize the tertiary structure into what's called the postfusion conformation and the transmembrane anchor added Both adenovirus vaccines encode full-length spike protein without the postfusion conformation stabilization mutations (say that 5 times fast!) but still add the membrane anchor. Sarah recommends this source for more information. So, these work similarly to the Pfizer/BioNTech and Moderna mRNA vaccines.  However, J&J and AstraZeneca Covid-19 vaccines require two steps to make the spike protein instead of one. They also require a special delivery agent to get into the cell nucleus. That's where adenoviruses kick in! Adenovirus Vectors Research There are about 50 years of research on adenovirus vectors as DNA delivery vectors. (8:48) Adenoviruses are basically common cold viruses that can cause illnesses ranging from cold-like symptoms to bronchitis, gastroenteritis, and conjunctivitis. They are non-enveloped DNA viruses that can't alter our DNA because (unlike retroviruses such as HIV or lentiviruses) wild-type adenoviruses do not carry the enzymatic machinery necessary for integration into the host cell's DNA.  Basically, they do not enter our cell's DNA. Adenoviruses deliver DNA that can enter the cell nucleus, are transcribed into mRNA, leaves the nucleus, and then translated into protein. That's exactly what makes them good vaccine platforms for infectious diseases. I used adenovirus vectors (Ad 5, the same used in the Russian sputnik V and China's CanSino covid-19 vaccines) for gene therapy research during my Ph.D. and even have a patent using them! Different Adenovirus Serotypes There are at least 88 human adenovirus types. Most serotypes cause mild illness, although data links adenovirus serotype 7 with more severe illness. (12:25) When used for gene therapy research or vaccines, research engineers them to be incapable of replicating and causing disease. There are adenovirus vector vaccines already in use. The rabies vaccine our pets get and the Ebola vaccine. One problem with using adenoviruses in vaccines is that people may already have antibodies to them, overwhelming them before they can do their assigned work.  Researchers get around that issue by using adenoviruses that humans are unlikely to have encountered before. The AstraZeneca/Oxford vaccine uses the ChAdOx1 platform based on a modified version of a chimpanzee adenovirus (causes colds in chimps and nothing in humans). The Johnson & Johnson & Janssen (J&J) vaccine uses a proprietary AdVac platform made up of recombinant human adenovirus (adv26).  It's the same platform used in the company's Ebola virus vaccine (approved in Europe) and its investigational Zika, RSV, and HIV vaccines.   Adjuvants in J&J and AstraZeneca Covid-19 Vaccines Like the mRNA vaccines, J&J and AstraZeneca Covid-19 vaccines don't require an adjuvant. (14:40) Stacy and Sarah talked about adjuvants in-depth in previous episodes. The viral vector itself helps to prime the immune system in a specific way to fight a virus- not generally the way aluminum-based adjuvants do. Then the real stimulant is the spike protein our cells make. The interesting thing about viral vector DNA vaccines is that our bodies react to it the same way as if we were actually sick with the illness.  Therefore, we get the same immune benefits as natural illness, minus the coronavirus's ability to manipulate the immune system and even more robust and durable immunity. Stacy shares that she was very surprised at how clean they were when she reviewed the vaccine ingredients. Sarah confirms this, saying newer vaccines (such as the recent ones for Covid) are missing many ingredients from early vaccines that cause many people to be hesitant about getting vaccinated. Ingredients in J&J: Recombinant, replication-incompetent adenovirus type 26 expressing the SARS-CoV-2 spike protein Citric acid monohydrate and trisodium citrate dihydrate - pH buffering, both naturally found in citrus fruit Ethanol 2-hydroxypropyl-β-cyclodextrin (HBCD), cyclic oligosaccharide containing seven D-(+)-glucopyranose units that are widely used to improve the aqueous solubility of various compounds, especially those containing a phenyl group, toxicology studies show very safe Polysorbate-80, emulsifier, pretty safe option Sodium chloride (aka salt) Source for Reference  Both AstraZeneca and J&J Covid-19 vaccines have reported that their vaccines were well tolerated with no serious safety concerns. However, there have been recent reports of blood clot issues, which Sarah and Stacy will cover.   J&J and AstraZeneca Covid-19 Vaccines Clinical Trial Results Like the mRNA vaccines, scientists could develop them quickly because of the decades of research scientists built from. (22:50) It's the same technology used in rabies vaccines for our pets and the Ebola vaccine (the only widespread vaccine used in humans). Johnson & Johnson One-shot (they are testing a 2-shot version test for efficacy increase) Stable at normal refrigerator temperatures, so cold-chain requirements are easier J&J Vaccine Fact Sheet FDA Fact Sheet for J&J Safety and Efficacy of Single Dose Efficacy against symptomatic disease 66.9% Vaccine efficacy was higher against severe–critical Covid-19 (76.7% and 85.4%) Prevented 100% of deaths from covid-19  No observable differences in vaccine efficacy according to sex, race, or ethnic group Similar to mRNA vaccines, no red flags from a safety perspective came up -- The incidence of serious adverse events balanced between the vaccine group and placebo. AstraZeneca Two shots 62% effective against symptomatic disease 100% against severe disease, hospitalization, and death Again, no red flag from a safety perspective Source for Reference    What About Adverse Side Effects? Stacy points out that the media always leads with the lowest number of something potentially problematic instead of leading with the bigger number, such as preventing 100% of deaths. (24:50) Sarah adds that the risk of developing a treatable reaction isn't the worst thing if the same treatment is keeping you from something way more serious - such as death. Stacy shares that it's not just the death toll, it's the risk of future complications and the way the symptoms can linger for months- two things she has personally experienced after having Covid last spring. She hates how the media is so ready to focus on the drama of the vaccine but completely skips over how much it's actually doing to protect us despite those few risks. AstraZeneca Not Approved In US Sarah explains that AstraZeneca's US trial is still ongoing and not yet approved for use. (34:00)  However, she points out that no "red flags" were presented during the clinical trials for either of these vaccines. That's important to put into context since both have shown complications when used in the community (which researchers expected, and Sarah explains why). The delay in the AstraZeneca trial lasted nearly seven weeks in the fall due to an adverse reaction in a UK participant. This was later determined as unrelated to the vaccine.  The initial trial results in November puzzled many experts from all around the world: The company combined data from its Brazil and UK groups, even though they had different sample sizes and demographics.  It also averaged the results of two different dosing regimens (one administered by mistake). Just 12% of participants in AstraZeneca's UK and Brazil trials were over 55 (but one quarter will be in US trial) Now, scientists hope that results from AstraZeneca's US trial will clear up much of the world's confusion.  According to a press release, key interim results of the trial, which included more than thirty thousand participants, and the data looked excellent. The vaccine appeared to be 79% effective at preventing "symptomatic COVID-19."  The press release said that no one given the vaccine in the trial became severely ill, hospitalized, or died due to COVID-19. Also, the study did not turn up any serious safety concerns. They'll likely apply for an EAU in the states in the next month or two. Why The Pauses Were Important The pause allowed the collection of more data to see how prevalent this adverse effect is. This way, they can find more cases, and the total was 15 out of about 8 million doses had this effect. The pause gives researchers time to educate patients on what to look out for and doctors on what to test for and how to treat. Sarah stresses that this is so important! Here's some perspective:  For one million J&J shots, researchers expect about 2 cases of TTP This contrasts with over 2,000 fewer deaths and 6,000 fewer Covid-related hospitalizations It's important to know that the agencies tasked with community monitoring are actually doing their job. This is how it's supposed to work! New stories have called this pause a bad thing, which has increased vaccine hesitancy. The media then inflamed the issue in an inaccurate and unhelpful way. Yes, plenty of people way they want Moderna or Pfizer instead of J&J right now. However, it takes time to educate people. Journalists need to focus on how the system works the right way to protect us instead of increasing fear. Just because AstraZeneca isn't approved yet doesn't mean it's unsafe. It means researchers want to devote enough time to understand the data as much as possible. Moderna, Pfizer, J&J and AstraZeneca Covid- 19 Vaccines Sarah explains that it's impossible to make an accurate comparison of efficacy between these trials. (47:10) Tests performed at different times, in different countries, with some variants may have impacted results. For example, the USA tested Moderna first, and now we see it undergoing testing elsewhere. The USA and Germany originally tested Pfizer (before B.1.1.7 became dominant). It is now undergoing testing elsewhere.  Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, and the United States tested the J&J vaccines. Brazil, South Africa, and the UK tested AstraZeneca initially. It is now running trials in the US, Japan, Russia, Kenya, and Latin America. Also, many areas define "symptomatic reactions" often vary. Sarah explains that to actually and accurately compare, we'd need a head-to-head trial with far fewer variables.   What About the Blood Clots? Stacy decides now is the time to talk about the elephant in the room: the reported risk of blood clots from the J&J vaccine. (52:45) Sarah explains that this is nowhere near clot risk from birth control pills (some many women take regularly), which is 1:1000. Also, it isn't a good comparison. "Run-of-the-mill" embolisms or thrombosis are easily treated. However, large ischemic stroke or myocardial infarctions, pulmonary embolism are more serious.  The rates of these types of blood clots after the vaccines are about what you'd expect in the population normally.  However, this rare adverse event following J&J and AstraZeneca Covid-19 vaccines is NOT run-of-the-mill.  https://www.bmj.com/content/372/bmj.n774 Cerebral venous thrombosis and portal vein thrombosis risk is 10x higher after covid-19 than after AstraZeneca vaccine https://www.bmj.com/content/373/bmj.n931 Immune Thrombotic Thrombocytopenia (ITT) Sarah underlines that calling this side effect "blood clots" isn't entirely accurate. What's actually happening ITT- an autoimmune response. Immune Thrombotic Thrombocytopenia (ITT) is blood clotting at the same time as low platelets. However, if treated properly and promptly, ITT is very treatable! This is so important because the normal way you treat blood clots (blood thinners like heparin) can cause death by hemorrhage.   With ITT, mortality is high (~90%) if untreated. The median age of onset 40 years and, like most autoimmune diseases, has a 3:1 female-to-male ratio. Stacy also reminds listeners that autoimmune diseases cannot be "caused" by something. Immune diseases are latent in the system until triggered, which is bound to happen at some point regardless. Autoimmune suffers aren't necessarily at higher risk. Some HLA risk alleles for other autoimmune diseases protect against TTP, and many don't increase risk at all. GREAT REVIEW PAPER  https://www.nejm.org/doi/full/10.1056/NEJMe2106315 https://www.nejm.org/doi/full/10.1056/NEJMoa2104882   Importance of J&J and AstraZeneca Covid- 19 Vaccines First, it's cheaper to make, ship, and store. So, they can get to places that are really tough to get the mRNA vaccines to, like rural America and developing nations. (1:12:10) Stacy and Sarah remind the audience that the pandemic isn't over until the whole world is protected. The high infection rates lead to the variants of concern, which we'll talk a bit more about next week.  This virus mutates slowly, but it has so many opportunities to mutate because of high infection rates, including in the USA. J&J is great for people who dislike needles, unhoused people, and people with schedules that make getting the second shot hard (e.g., truckers or flight attendants who travel a lot).  More References for J&J and AstraZeneca Covid-19 Vaccines Watanabe, Y. et al. (2021) Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. ACS Central Science, ​See source here https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext   Final Thoughts These vaccines are just more tools in our toolbox to get through this pandemic. (1:15:10) Stacy and Sarah have dedicated the last 8 years to do this podcast to focus on everyone's health, safety, and wellness. Stacy adds that we often get so caught up in our own health, wellness, and safety that we forget part of what a vaccine does is protect others.  It's easy to be fearful and hesitant because there's so much to the science that an average person might not easily understand. And the more the media talks about it from a negative perspective, the less confident people get to go and get something that might be lifesaving- not just for themselves but others around them. Stacy takes a minute to talk about the difference between one mild/moderate complication right after the vaccine (heavier period) compared to more long-term complications from "long hauler syndrome" (brain fog, i.e., brain damage). Stacy reminds listeners that Patreon is a great way to connect. So if you haven't joined the family yet, be sure to pop over for bonus content like how Stacy and Sarah really feel about the topics they discuss. Thanks so much for listening, and we'll see you next week!

Generation X stepped up in a big way this week when the demographic became eligible for the AstraZeneca-Oxford vaccine. The U of A's Dr. Lynora Saxinger talks with us about the meteoric uptake of the AZ shot and how this could shift Alberta's third wave. Plus we mark Earth Week with a tour of a local shop that's making small changes for big sustainability, we get some tips about ways to reduce our waste, and associate producer Patrick Connolly takes us south of the equator to meet an Oilers' fan in the unlikeliest of places.

O Ministério da Saúde alertou que 1,5 milhão de brasileiros deixaram de receber a segunda dose de um dos imunizantes contra a Covid-19. Essa parcela da população tomou a primeira injeção da CoronaVac ou da AstraZeneca/Oxford, mas não completou o esquema vacinal. Por isso não há proteção suficiente contra a doença, o que pode dificultar o combate da pandemia. De acordo com as autoridades, São Paulo é o estado com o pior índice, com mais de 343 mil atrasados. Na sequência, aparecem Bahia e Rio de Janeiro.A questão é importante, no entanto, não apenas para a sua saúde pessoal, mas também para a saúde do país e a retomada econômica. E para falar sobre o assunto, o Direto ao Ponto recebe Fernando Ritter, Diretor da Vigilância de Saúde de Porto Alegre.

A paralisação da produção da Coronavac por falta de insumos, o processo de impeachment do ex-governador do Rio de Janeiro, Wilson Witzel, e o alerta da Anvisa para a vacina da AstraZeneca/Oxford estão entre os destaques do 5 Fatos Manhã desta quinta-feira, 8 de abril de 2021. See omnystudio.com/listener for privacy information.

The Bill Kelly Show Podcast: The province is seriously considering another stay at home order and possibly a state of emergency. Premier Doug Ford warned earlier this week stricter measures were coming, and we'll find out later today what we can and can't do. ALSO: A year into Ontario's battle against the COVID-19 pandemic, why does it feel like the provincial government is still making decisions based on guesswork? Are vaccines getting into the arms they should? And has public trust in elected officials completely eroded? GUEST: Laura Babcock, President, PowerGroup - A team of doctors at Hamilton's McMaster University is preparing to test blood samples from across Canada in search of a rare type of clot linked to the AstraZeneca-Oxford COVID-19 vaccine. There have been no cases of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) in Canada, but there have been cases in Europe, prompting NACI to recommend pausing administration of the AstraZeneca-Oxford vaccine to those under age 55. The McMaster team is preparing to screen blood samples of Canadian patients who may have had VIPIT. GUEST: Dr. Ishac Nazy, Associate Professor in the department of Medicine and principal investigator with the McMaster Platelet Immunology Laboratory - Despite the lack of data documenting benefits to children, and emerging evidence of several drawbacks and harms, the Ontario government is discussing making full-time online schooling a permanent "choice" in public education. For children, fully online learning creates the conditions for further educational inequality. It is a particular risk for children with special education needs. With all the issues implied by full-time online learning, why would Ontario consider making this a permanent feature of public education?  GUEST:  Dr. Lana Parker, Assistant Professor at the Faculty of Education at the University of Windsor

La vacuna desarrollada por la Universidad de Oxford y la empresa AstraZéneca ha sido aprobada para su uso de emergencia en el Reino Unido. En las próximas semanas los expertos de todo el mundo buscarán la respuesta a varias preguntas cruciales sobre esta vacuna entre las personas que la reciban. Gracias por sus comentarios y apoyo, recuerde que puede apoyarnos donando en PayPal https://www.paypal.com con el correo elexplicadorpatrocinio@gmail.com y en Patreon en El Explicador Enrique Ganem patreon.com/elexplicador_enriqueganem . Lo invitamos a suscribirse a este canal para recibir avisos de nuevas publicaciones y a visitar nuestra página http://www.elexplicador.net. En el titulo de nuestros trabajos aparece en primer lugar la fecha año/mes/día de publicación, lo que facilita su consulta cronológica. Siempre leemos sus comentarios, muchas veces no tenemos tiempo para reponder a cada uno personalmente pero son leídos y tomados en cuenta, los iremos respondiendo según nos sea posible. Este es un espacio de divulgación científica en el que nos interesa informar de forma clara y amena, que le invite a Ud. a investigar sobre los temas tratados y Ud. forme su propia opinión. Serán borrados los comentarios que promuevan la desinformación, charlatanería, odio, bullying, violencia verbal o incluyan enlaces a páginas que no sean de revistas científicas arbitradas, sean ofensivos hacia cualquier persona o promuevan alguna tendencia política ya sea en el comentario o en la fotografía de perfil. Aclaramos que no somos apolíticos, nos reservamos el derecho de no expresar nuestra opinión política, este es un canal cuya finalidad es la divulgación científica. Gracias por su preferencia. AVISO: En la área inferior de nuestros vídeos aparece un recuadro de la Secretaría de Salud con una liga, queremos aclarar que estos letreros aparecen sin nuestro conocimiento o notificación previa alguna y que no nos están patrocinando en forma alguna. ACLARACIÓN IMPORTANTE: El virus SARS- CoV-2 y la enfermedad COVID-19 SI EXISTEN, SON REALES. Le sugerimos que siga atentamente las recomendaciones de la Secretaría de Salud: higiene, mascarilla o tapaboca cuando salga de su domicilio y sobre todo quédese en casa cuando no sea indispensable salir.

Las pruebas de nivel III de la vacuna desarrollada por la Universidad de Oxford y la empresa AstraZeneca se detuvieron después que uno de los miles de participantes sufrió un "evento indeseable". Esto no significa que será necesario modificar o descartar la vacuna. Gracias por sus comentarios y apoyo, recuerde que puede apoyarnos donando en PayPal https://www.paypal.com con el correo elexplicadorpatrocinio@gmail.com y en Patreon en El Explicador Enrique Ganem https://www.patreon.com/user?u=18159632. Lo invitamos a suscribirse a este canal para recibir avisos de nuevas publicaciones y a visitar nuestra página http://www.elexplicador.net. En el titulo de nuestros trabajos aparece en primer lugar la fecha año/mes/día de publicación, lo que facilita su consulta cronológica. Siempre leemos sus comentarios, muchas veces no tenemos tiempo para reponder a cada uno personalmente pero son leídos y tomados en cuenta, los iremos respondiendo según nos sea posible. Este es un espacio de divulgación científica en el que nos interesa informar de forma clara y amena, que le invite a Ud. a investigar sobre los temas tratados y Ud. forme su propia opinión. Serán borrados los comentarios que promuevan la desinformación, charlatanería, odio, bullying, violencia verbal o incluyan enlaces a páginas que no sean de revistas científicas arbitradas, sean ofensivos hacia cualquier persona o promuevan alguna tendencia política ya sea en el comentario o en la fotografía de perfil. Aclaramos que no somos apolíticos, nos reservamos el derecho de no expresar nuestra opinión política, este es un canal cuya finalidad es la divulgación científica. Gracias por su preferencia. AVISO: En la área inferior de nuestros vídeos aparece un recuadro de la Secretaría de Salud con una liga, queremos aclarar que estos letreros aparecen sin nuestro conocimiento o notificación previa alguna y que no nos están patrocinando en forma alguna. ACLARACIÓN IMPORTANTE: El virus SARS- CoV-2 y la enfermedad COVID-19 SI EXISTEN, SON REALES. Le sugerimos que siga atentamente las recomendaciones de la Secretaría de Salud: higiene, mascarilla o tapaboca cuando salga de su domicilio y sobre todo quédese en casa cuando no sea indispensable salir.

This week we hand The Dose over to you. Canadians have been on a roller-coaster with changing guidance on the AstraZeneca-Oxford vaccine, so we put your questions to infectious disease specialist Dr. Zain Chagla who, despite rising COVID-19 numbers and vaccine concerns, remains optimistic.

22 de março de 2021 • Episódio #197 do podcast Economia em Tempos de Pandemia, por Monica de Bolle. Transmissão sobre novos resultados da vacina AstraZeneca/Oxford.

Grande parte dos ministros do Supremo Tribunal Federal (STF) deve votar contra a ação de inconstitucionalidade apresentada pelo presidente Jair Bolsonaro (sem partido) para derrubar as medidas restritivas dos governos do Distrito Federal, da Bahia e do Rio Grande do Sul e o monitor Caio Mello (do curso de Jornalismo) diz quando a decisão deve ser definida. Ele também explica o porquê que o laboratório indiano Instituto Serum irá atrasar o envio de doses da AstraZeneca/Oxford para o Brasil.

This week we we start by checking out some science: travel faster than speed of light(?) and the wonderful 3D-model of the Antikythera mechanism. We look back at the birth of the Hungarian Skeptic Society and we poke the pope for being a bigot about gay marriage. We look at the covid vaccine situation and especially if the AstraZeneca / Oxford vaccine appears safe, before we check out the news: New book: Fake news a threat to democracy? New tool to help students detect fake images and videos People with high emotional intelligence less susceptible to fake news? Water ‘vitalizer' banned for possible interference with radio devices Social media watchdog: Instagram highly responsible for the spreading of misinformation? New book out: ‘Don't get mixed up with food' Enjoy! Segments: Intro; Greetings; This Week; Pontus Pokes the Pope; Covid-19 Update; News; Quote and Farewell; Outro; Out-takes The Events Calendar: https://theesp.eu/events_in_europe

As further European countries announce precautionary suspension of the AstraZeneca/Oxford vaccine over fears it may have caused blood clots in a very small number of people, Claudia talks to BBC Health Editor James Gallagher about what the data really tells us about the safety of this vaccine. Tanzania and Covid. Claudia talks to BBC Africa Correspondent Leila Nathoo about Covid in Tanzania. President Magufuli was one of Africa's most prominent Covid-19 sceptics, and is now rumoured to have died of the disease himself. Last year he said the disease had been eradicated from Tanzania by three days of national prayer but does Tanzania have a hidden epidemic? Vaccine Side Effects. Claudia discovers why there seems to be such a difference in how people have reacted to the vaccine, from no side effects at all, to mild flu like symptoms. She looks at how the vaccine triggers an immune response, and why it can't give you Covid. Haitians in Chile. Chile has long been a destination for immigrants from other countries in the region because there are more work opportunities. People from places like Venezuela, Bolivia and Peru make up around 8 percent of the 19 million population and the number is growing every year. What's surprising is that the third biggest group of immigrants in Chile come from the Caribbean country Haiti. Health services are quickly having to learn ways to integrate their new patients who have different approaches to healthcare as Jane Chambers reports. Presenter: Claudia Hammond Producer: Alexandra Feachem (Picture: A vial of AstraZeneca vaccine at Krakow University Hospital, Poland in February 2021. Photo credit: Beata Zawrzel/NurPhoto/Getty Images.)

The AstraZeneca- Oxford university COVID-19 vaccine has been paused by a number of countries in Europe after reports of blood clotting and Deep Vein Thrombosis in some participants arose. Countries including France Germany, Italy, Spain, Portugal and Norway have put a halt on the rollout of the innoculation programme for now and are examining the cases that have occurred.   While they carry out assessments, the World Health Organisation as well as the European Union's vaccine regulator have played down the issue for now. They have highlighted two important points. One, there is no indication that the vaccine is linked to an increased risk of blood clots. Two, the number of cases in vaccinated people was no higher than in the general population.  In India, the Serum Institute of India is manufacturing the Oxford-AstraZeneca vaccine as Covishield and 1.5 crore doses have already been administered.   At a time when COVID-19 cases have seen a spike across India and Europe and the vaccination process is underway, a number of key questions have emerged. Why has this become an issue in the EU? Should India, which manufactures the same vaccine, be worried?   The Quint spoke with Dr Rahul Bhargava, Director and Head, Haematology and Bone Marrow Transplant at Fortis Memorial Research Institute, Gurugram 

Novo ministro na saúde, vacina da Astrazeneca/Oxford sendo suspensas em muitos países. Juros compostos e o FIRE.

Nesta sexta-feira (12), a Agência Nacional de Vigilância Sanitária (Anvisa) anunciou o registro à vacina AstraZeneca/Oxford, com etapa de fabricação no Brasil, e do primeiro medicamento para pacientes hospitalizados com Covid-19. O monitor Caio Mello (do curso de Jornalismo) explica qual antiviral é esse e de que forma ele será administrado. Além disso, saiba como foi a conclusão da aprovação, em segundo turno, da PEC Emergencial na Câmara dos Deputados.

CNN Mundo #8 - 2ª temporada: Esta semana, o governo brasileiro finalmente confirmou a intenção de adquirir as vacinas Pfizer, da Johnson & Johnson's e do laboratório indiano Bharat Biotech, fabricante da Covaxin. O Bharat Biotech divulgou no último dia 3 que o imunizante tem 81% de eficácia. Neste episódio do CNN Mundo, Lourival Sant'Anna fala com o repórter da CNN Mathias Brotero, que esteve na Índia e traz notícias sobre a Covaxin e sobre a pandemia no país. Também na pauta, os entraves em torno da vacina da AstraZeneca/Oxford, que está enfrentando resistência da população europeia, a reforma policial nos Estados Unidos e a condenação do ex-presidente francês Nicholas Sarkozy. See omnystudio.com/listener for privacy information.

Covid-19-Impfungen werden weit mehr Schaden anrichten, als sie Nutzen bringen, sagt der Infektionsepidemiologe Sucharit Bhakdi.Ein Standpunkt von Peter F. Mayer. Wenn jemand unbequeme Dinge äußert, kann man ihn neutralisieren, indem man ihm vorwirft, kein Experte zu sein. Ist jemand jedoch ein ausgewiesener Experte auf einem Fachgebiet und äußert sich trotzdem oder gerade deshalb unbequem, kann man ihm nur noch durch unqualifizierte Diffamierung beikommen. So geschah es Dr. Sucharit Bhakdi, der zu einem der bekanntesten wissenschaftlichen Gesichter der „Maßnahmen-Kritiker-Szene“ avanciert ist. Die neuartigen Covid-19-Impfstoffe halten nicht, was sie versprechen, sagt er. Sie bergen Langzeitrisiken, die zum jetzigen Zeitpunkt noch gar nicht abzuschätzen sind. All das erklärt Bhakdi detailliert in seinem neuen Buch „Corona unmasked. Neue Zahlen, Daten, Hintergründe“, das er zusammen mit Karina Reiss gerade herausgebracht hat. Das erste Kapitel über Impfungen stellte er in einer Diskussion mit den Professoren Andreas Sönnichsen und Martin Haditsch vor. In vielen Ländern werden seit Mitte Dezember 2020 im Wesentlichen drei Gentechnik-Impfstoffe mehr oder weniger massenhaft verimpft: die mRNA-Impfstoffe von Pfizer/BioNTech und Moderna sowie der Vektorimpfstoff von AstraZeneca/Oxford. Seither sind soziale Medien voll mit Berichten über steigende Todesfälle, schwere Nebenwirkungen und Infektionen nach der Impfung. Sogar Mainstream-Medien berichten darüber. Da die negativen Berichte offenbar als bedrohlich empfunden werden, eilen nun auch Faktenchecker herbei, um Nebelgranaten zu werfen. Um sich selbst ein Urteil über diese Meldungen bilden zu können, ist es nützlich zu verstehen, wie diese drei Impfstoffe wirken, in welche Zellen die mRNA- oder Vektor-Partikel eingeschleust werden sowie welche Wirkungen und Nebenwirkungen sie dort entfalten können....weiterlesen hier: https://kenfm.de/die-verschlimmbesserung-von-peter-f-mayer/ Jetzt KenFM unterstützen: https://de.tipeee.com/kenfm https://flattr.com/@KenFM Dir gefällt unser Programm? Informationen zu weiteren Unterstützungsmöglichkeiten hier: https://kenfm.de/support/kenfm-unterstuetzen/ Du kannst uns auch mit Bitcoins unterstützen. BitCoin-Adresse: 18FpEnH1Dh83GXXGpRNqSoW5TL1z1PZgZK Abonniere jetzt den KenFM-Newsletter: https://kenfm.de/newsletter/ KenFM jetzt auch als kostenlose App für Android- und iOS-Geräte verfügbar! Über unsere Homepage kommt Ihr zu den Stores von Apple und Google. Hier der Link: https://kenfm.de/kenfm-app/ Website und Social Media: https://www.kenfm.de https://www.twitter.com/TeamKenFM nhttps://www.instagram.com/kenfm.de/ https://soundcloud.com/ken-fm See acast.com/privacy for privacy and opt-out information.

Com a vacinação em curso no Brasil, muitas dúvidas em relação à imunização e possíveis contraindicações surgem. Por enquanto, apenas a CoronaVac e a da AstraZeneca/Oxford são ministras nas campanhas do Ministério da Saúde. Enquanto isso, outras farmacêuticas seguem negociando com o governo brasileiro. Se você sofre de alguma doença crônica, autoimune ou está em tratamento médico deve se atentar para alguma restrição? Quem explica é Daniel de Oliveira Gomes. Ele é imunologista, pesquisador e professor da Ufes. Acompanhe!

O programa Covax da OMS envia para Gana, na África, as primeiras 600 mil doses da vacina AstraZeneca/Oxford, fabricadas pelo Instituto Serum, da Índia. As informações com a repórter Juliana Medeiros. --- Send in a voice message: https://anchor.fm/cultura-fm-braslia/message

UK Prime Minister Boris Johnson says lives will be 'incomparably better' in England's spring and summer as he sets out a plan to fully ease lockdown rules by June 21.A paper published yesterday shows the two vaccines approved and in use in Britain showed high efficacy rates in trials.The first doses of Pfizer-BioNTech and AstraZeneca-Oxford vaccines in Scotland led to a substantial fall in Covid-19 hospital admissions.Dr Chris Smith, medical consultant of virology at Cambridge University and founder of the Naked Scientist podcast, joined Kerre McIvor this morning to update us on the latest developments from Britain.LISTEN ABOVE

As the U.S. hits the half-million death mark from COVID-19 -- a grim milestone that is equal to roughly the entire population of Atlanta and more than that of Miami -- a new weapon is being added to the COVID-19 vaccine arsenal. Johnson & Johnson is seeking emergency use authorization for what would become the U.S.'s first one-dose and non-mRNA COVID vaccine. It employs adenovirus vectors, a technology that has been used in labs for decades and was approved for the Ebola vaccine by the FDA in December 2019. It's the same technology that AstraZeneca/Oxford and Sputnik V use. Still, questions remain on how these vaccines may be different than mRNA or similar enough to other existing shots to encourage vaccine uptake. To explain how adenovirus vectors work and what to expect from the new products, Daniel Griffin, MD, PhD, chief of infectious disease at ProHEALTH Care, an Optum unit, joins us on this week's episode.

De dos meses a esta parte la farmacéutica AstraZeneca está abonada al escándalo. No hay semana en la que no comparezca en las portadas de los diarios por asuntos que van mucho más allá del diseño y fabricación de fármacos. A principios de año pudimos asistir a una agria disputa entre la empresa y la Comisión europea. Un mes más tarde el problema era de orden médico, las autoridades sanitarias de diferentes países europeos estudiaron prohibir la administración de viales de la vacuna fabricada por esta compañía a mayores de 65. Aseguran que en los ensayos clínicos que realizaron AstraZeneca y la Universidad de Oxford no hubo una muestra suficiente personas mayores de 65 años como para garantizar la efectividad en ese rango edad. El punto a debate es que varios expertos sostienen que en los estudios previos la inmensa mayoría de los voluntarios tenía menos de 55 años por lo que se desconocería la eficacia real de la profilaxis también en el grupo de entre 55 y 65 años. Este de la edad ha sido sólo uno de los campos de batalla en los que esta vacuna basada en adenovirus ha tenido que combatir. Eso ha llevado a que muchas personas desconfíen de ella y la rechacen. Así que lo suyo es plantearse una serie de preguntas clave sobre la polémica vacuna de AstraZeneca, preguntas como ¿qué contiene la vacuna de AstraZeneca/Oxford?, ¿es un virus inactivado?, ¿cómo se ha diseñado?, ¿en qué se diferencia de Moderna y Pfizer?, ¿es una vacuna segura?, ¿por qué hacen falta dos dosis?, ¿cómo influye el tiempo transcurrido entre las dosis?, ¿puede administrarse a cualquier grupo de edad?, ¿es conveniente si has pasado la COVID-19 hace menos de 6 meses?, ¿se la pueden poner embarazadas o madres en lactancia?, ¿es recomendable para personas con patologías previas, hipertensión, problemas cardiovasculares, alergias?, ¿cuál es su efectividad?, ¿lo es contra las nuevas variantes del virus?, ¿por qué se está ensayando mezclarla con otras vacunas?, ¿reduce también la transmisión?, ¿por qué tienen problemas en la manufactura y retrasos en las entregas? Todas vamos a tratar de responderlas hoy en La ContraCrónica de la mano de Andrea Martos, bioquímica de la Universidad de Cambridge que visita de nuevo el programa para poner algo de luz sobre este asunto que tanto preocupa a todos. Apoya La Contra en: · Patreon... https://www.patreon.com/diazvillanueva · iVoox... https://www.ivoox.com/podcast-contracronica_sq_f1267769_1.html · Paypal... https://www.paypal.me/diazvillanueva Sígueme en: · Web... https://diazvillanueva.com · Twitter... https://twitter.com/diazvillanueva · Facebook... https://www.facebook.com/fernandodiazvillanueva1/ · Instagram... https://www.instagram.com/diazvillanueva · Flickr... https://www.flickr.com/photos/147276463@N05/?/ · Pinterest... https://www.pinterest.com/fernandodiazvillanueva Encuentra mis libros en: · Amazon... https://www.amazon.es/Fernando-Diaz-Villanueva/e/B00J2ASBXM Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Ontem, 10 de fevereiro, o Congresso Nacional instalou uma comissão mista, formada por deputados e senadores, para analisar o Orçamento de 2021 e o monitor Caio Mello (do curso de Jornalismo) explica como será formado o colegiado. Ele também traz detalhes sobre a recomendação da OMS (Organização Mundial da Saúde) para que o intervalo entre a primeira e a segunda dose da vacina AstraZeneca/Oxford – principal aposta do governo brasileiro – seja de dois a três meses.

The South African government has decided to pause its roll-out of the Astrazeneca-Oxford vaccine because of disappointing results of the vaccine's effectiveness against the most common variant in the country in a trial of young people. And is there any good evidence from trials elsewhere that this vaccine reduces the chances of people spreading the coronavirus to others, as well as preventing severe illness and death? How do you test whether a vaccine prevents or reduces transmission of the coronavirus? Claudia's regular guest epidemiologist Professor Matt Fox of Boston University discusses the issues. Claudia talks to two ovarian cancer specialists, Dorothy Lombe in Zambia and Georgia Funtes Cintra in Brazil about the challenges and success stories in providing treatment and care for women with this kind of cancer. The Global Cancer Coalition Network has released a report documenting the worsening situation in cancer care in 104 countries because of the coronavirus pandemic. Dorothy and Georgia tell us how the disruption has affected their patients. As Donald Trump's impeachment trial gets underway, reporter Alison van Diggelen looks at social science research on political polarisation in US society, and an experiment run by Stanford University to heal divisions. Does a frequent intake of spicy food influence a person's risk of developing cancers of the gut? Studies to date have been inconclusive but now a massive study following 500,000 people comes out of China, finding that spicy food is protective. Spicy food appears to lower the risk of getting cancer of the oesophagus and, to a lesser extent, the stomach as well. Presenter: Claudia Hammond Producer: Andrew Luck-Baker (Picture: A doctor walks in the Respiratory & Meningeal Pathogens Research Unit at Chris Hani Baragwanath Hospital in Soweto, South Africa in July 2020. Photo credit: Luca Sola/AFP/Getty Images.)

A Agência Nacional de Vigilância Sanitária (Anvisa) decidiu dispensar a aprovação de vacinas que forem enviadas ao Brasil pela Organização Mundial da Saúde (OMS). De acordo com a Agência, a decisão "reduz a duplicação de esforços regulatórios", relata a CNN (https://bit.ly/3cYrpQ8). A partir de agora, todo imunizante enviado pelo consórcio Covax Facility, iniciativa da OMS que prevê a distribuição global de vacinas, poderá ser aplicada imediatamente. O consórcio prevê que o Brasil receba apenas 1,6 milhão de doses da vacina da AstraZeneca/Oxford no primeiro trimestre e 6 milhões no segundo trimestre, aponta a Folha de S.Paulo (https://bit.ly/3cY801F). A covid fez 1.340 novas vítimas nas últimas 24 horas, elevando para mais de 233 mil o total de vidas perdidas, relata O Globo (https://glo.bo/3aONaix). Mais de 4 milhões de doses de vacina já foram aplicadas em todo o Brasil.

A África do Sul resolveu suspender o uso da vacina contra a covid-19 desenvolvida pela AstraZeneca e a Oxford, depois de um estudo indicar que o imunizante não protege contra uma variante local da doença. Segundo matéria do G1 (http://glo.bo/2YRt3e9), a eficácia das doses se mostrou limitada contra doenças leves causadas pela cepa identificada no país, que apresenta uma transmissão mais acelerada. Para casos graves, hospitalizações e mortes, a capacidade de proteção não foi determinada. Cientistas do Ministério da Saúde sul-africano agora vão analisar os dados para decidir a melhor forma de proceder. A vacina da AstraZeneca/Oxford é a principal aposta do governo brasileiro na imunização contra a covid-19, como lembrou notícia de O Globo (http://glo.bo/2YXDqgc). O Brasil também lida com variantes do vírus, como a encontrada no Amazonas, que, conforme especialistas, têm mutações similares às da cepa identificada na África do Sul. Outra variante que preocupa a comunidade científica foi encontrada no Reino Unido e tem se espalhado rapidamente nos Estados Unidos. Reportagem da CNN (http://cnn.it/3oWB1NG) aponta que essa cepa, que é conhecida como B.1.1.7, tem uma taxa de transmissão 35% a 45% maior do que as mutações mais comuns da covid-19, e a contaminação tem dobrado a cada cerca de dez dias no país. A perspectiva é de que essa variante se torne a mais comum nos Estados Unidos a partir de março.

In this episode:  Instead of efficacy, look at the secondary endpoints as vaccine data is being released Whilst the evidence for giving the AstraZeneca Oxford vaccine in patients over 65 yrs is small it is still a reasonable option TGA is maintaining a very watchful eye on all new vaccines  It is possible Australia will have 5 different vaccines available by the end of 2021  Host: Dr David Lim | Total time: 27 mins Guest: Dr Gary Grohmann, Virologist; Vaccine Manufacturing Expert; Former Director of Immunobiology and WHO ERL at the TGA, Office of Laboratories and Scientific Services   Register for our upcoming FREE WEBCAST Tuesday 2 February 2020 | 7:00pm-9:00pm AEDT Click here to register now! See omnystudio.com/listener for privacy information.

Acompanhe o DOSE CERTA, o seu boletim de saúde na programação da Hits Prime FM todos os dias. Apresentação Dr. Júlio Casé, médico de família e comunidade. Acesse nosso site www.fmhits.com.br para ouvir online. BAIXE O APP PRIME e ouça sem limites, na AppStore httpbit.lyIOS_PRIME ou na GooglePlay httpbit.lyPRIMEAPP_GooglePlay. --- Send in a voice message: https://anchor.fm/quadros-da-prime-fm/message

O Alto Tietê recebe hoje (26/01) um novo lote de vacinas contra o coronavírus, desta vez da fabricante AstraZeneca/Oxford. Serão 11.470 doses para as dez cidades da região, informou ontem o Consórcio de Desenvolvimento dos Municípios do Alto Tietê (Condemat), destinadas para a imunização de mais uma parcela do grupo prioritário de trabalhadores da Saúde e asilados. Em Mogi das Cruzes l, o Ministério Público foi acionado ontem (25/01) com um pedido para que os promotores fiscalizem a distribuição das vacinas sob responsabilidade da Prefeitura de Mogi contra a Covid-19 e apurem eventuais “fura-filas” na cidade, a Rádio Metropolitana segue acompanhando o parecer da Prefeitura. Acompanhe os destaques com o cientista político, Samuel Oliveira. O cientista político comenta ainda sobre o cenário das eleições para a presidência da Câmara e do Senado e sobre as novas polêmicas entre o governador governador João Dória e o presidente Jair Bolsonaro.

Secretaria Estadual da Saúde começa a distribuição das doses da vacina AstraZeneca/Oxford para as coordenadorias regionais de saúde Última semana para obter desconto no IPVA 2021 Candidatos que não puderam realizar o Enem podem solicitar a reaplicação da prova a partir de hoje

A realização do Exame Nacional do Ensino Médio – ENEM em meio ao contexto de pandemia do novo coronavírus, sem clareza na comunicação aos estudantes a respeito das garantias sanitárias para a participação, e a aquisição de medicamentos sem eficácia para a Covid-19 são dois exemplos de custos (distintos, é verdade) provenientes de uma das diversas características ruins do atual (des)governo: incompetência. Além dos reflexos da ausência de governo central, este programa discute ainda a liberação do carregamento de dois milhões de doses da vacina da AstraZeneca/Oxford; mudança de lado na briga pela presidência da Câmara; e o resultado positivo para Covid-19 do ex-presidente Lula. De segunda a sexta, sempre na faixa das 21h, o #JCInforma é o seu ponto de encontro com os cronistas do JC e as principais manchetes do dia. Neste espaço, os destaques dão o tom da conversa comandada pelo cronista Pedro Araujo, editor de Política no Recife, com a participação, em rodízio diário, de Claudio Porto e Adriano Garcia, ambos editores de Política em São Paulo, e Ulisses Santos, editor em Porto Alegre.

A Gente Explica: O anúncio de uma eficácia de cerca de 50,4% feito pelo Instituto Butantan rendeu frustrações para algumas pessoas, que esperavam um índice maior. Ainda mais porque é quase inevitável não comparar com os resultados de outras vacinas como o da Pfizer (com 95% de eficácia), Moderna (com 94% de eficácia), Sputnik V ( com 90%) e Astrazeneca/Oxford (com eficácia entre 62 a 90%). Apesar disso, especialistas garantem que o número mais baixo não significa que a Coronavac seja menos valiosa ou possa ser descartada no atual momento. Entenda a eficácia e se devemos ou não confiar na vacina.

A Gente Explica: O anúncio de uma eficácia de cerca de 50,4% feito pelo Instituto Butantan rendeu frustrações para algumas pessoas, que esperavam um índice maior. Ainda mais porque é quase inevitável não comparar com os resultados de outras vacinas como o da Pfizer (com 95% de eficácia), Moderna (com 94% de eficácia), Sputnik V ( com 90%) e Astrazeneca/Oxford (com eficácia entre 62 a 90%). Apesar disso, especialistas garantem que o número mais baixo não significa que a Coronavac seja menos valiosa ou possa ser descartada no atual momento. Entenda a eficácia e se devemos ou não confiar na vacina.

Los mercados globales mostraron rendimientos positivos en mercados desarrollados (+2,4%), siendo impulsados principalmente el avance registrado en el Reino Unido (+5,8%), y en Asia Desarrollado (+4,1%). Del mismo modo, los mercados emergentes cierran la semana con retornos positivos (+4,8%), destacando Asia Emergente (+5,3%). La bolsa local cierra positiva, liderando los retornos de la región, (+9,6% en USD). Lo anterior, se dio en una semana positiva para los activos de riesgo, a pesar de estar marcada por los disturbios que rodearon el proceso de ratificación de Biden, la elección de los senadores en Georgia, medidas de confinamiento a causa de la nueva cepa de coronavirus y las primeras aplicaciones de la vacuna de AstraZeneca-Oxford. Adicionalmente, la OPEC+ alcanzó un acuerdo en su primera reunión mensual , luego que Arabia Saudita se comprometiera voluntariamente a reducir su producción en 1 mm de barriles diarios, permitiendo incrementos menores para Rusia y Kazajistán, llevando al WTI a transar sobre los US$50 el barril por primera vez desde febrero.

Morocco Health Ministry on Wednesday said the Government has authorized for emergency use the coronavirus vaccine developed by AstraZeneca and the University of Oxford.The government says it has ordered 65 million doses of AstraZeneca’s vaccines as well as from the Chinese firm Sinopharm.It says preparations for rolling out the vaccine are very advanced but has not given a date for injections to start.

India's nationwide vaccination drive is scheduled to begin in January with the AstraZeneca-Oxford shot, The Centre and farm unions protesting against a set of laws will hold their seventh round of negotiations, Sourav Ganguly who suffered a heart attack during his morning exercise session is now stable & other top stories in your morning news bulletin.

Manila Bulletin News On Web, Thurs, December 31, 2020 Here are your news on web: - DFA advises incoming travelers, including Filipinos, to reschedule travel plans to a later date - DAR identifies 230K-HA gov't-owned lands for agri-graduates - Central Visayas cops warned against indiscriminate firing - US expects to approve UK-backed Astrazeneca-Oxford vaccine in April - K-pop girl group Gugudan disbands after 4 years - Michael Jordan wins lawsuit over name right disputes in China For more news and details, visit our website www.mb.com.ph and get a copy of Manila Bulletin newspaper tomorrow. You may also subscribe to our newsletter at https://mb.com.ph/newsletter-subscrip... to have the day's latest news delivered to your inbox.

On the weekend podcast, we have a Brexit discussion, talk about our yearly returns, why the markets didn't rally on the AstraZeneca / Oxford vaccine news & the three things you can do to improve you investment performance.

UTILIDADES GRATUITAS PARA TRADERS AQUÍ >> https://linktr.ee/inversionesytrading Pre-Mercado Americano – Destacados: Bolsa Americana opera al alza en el penúltimo día del año. El Bitcoin alcanza un nuevo máximo histórico al llegar a 28.587. El Reino Unido aprueba el uso de emergencia de la vacuna de AstraZeneca/Oxford. Recuerda seguirnos en nuestro Canal de Youtube para acceder a nuestras Transmisiones en Vivo donde cubrimos eventos de alto impacto en los mercados. https://www.youtube.com/inversionesytrading #forex #inversiones #trading #trader #dolar #dinero #spx #sp500 #nasdaq #dowjones #wallstreet #stocks #acciones #inversion #indices #oil #petroleo #covid #europa #acciones #money #daytrading #FOREXENVIVO #FOREXTRADING #DAYTRADING #AIE #BITCOIN #PFIZER #VACUNA #UK #FDA #COVID #BTC #Ripple $XRP $BTC $ETH #Criptomonedas #aprederdetrading #cursos #clases #NFP #FOMC #UK #UKcovid #trump #economia #noticias #Brexit #astrazeneca

Dr. Dawn gets the Pfizer-BioNTech vaccine and describes the expected short term side effects; How to improve the efficacy of a variety of masks; The anti-viral importance of Vitamin C, especially in fighting Coronavirus; Combating nausea during pregnancy and discussion of COVID-19 vaccine during pregnancy; Comparison of the conventional AstraZeneca-Oxford vaccine vs. new mRNA approach; Suggestions to encourage getting any Coronavirus vaccine; LED and laser therapy techniques for skin treatment are evaluated; Review of Bioelectric Magnetic Energy Regulation therapy for pain

Podcast: New Scientist Weekly (LS 49 · TOP 1% what is this?)Episode: #44: When we'll get the vaccine; fast-expanding universe; lunar missionsPub date: 2020-11-27Vaccine scientist Katrina Pollock answers some of the biggest questions about covid-19 vaccines: when are we going to get one, and when will life go back to normal? A clinician at Imperial College London, Katrina is working on both the Imperial mRNA vaccine trials, and the AstraZeneca-Oxford vaccine trials. She discusses vaccine safety, and the finding in trials that a low-dose of the AstraZeneca vaccine caused a bigger immune response. Also on the podcast, science writer Stuart Clark explains why the unusually fast expansion of our universe might require a rethink of Einstein's general theory of relativity. We discuss China's Chang'e 5 mission to bring back samples of moon rocks for the first time in over 40 years. We also hear about the startling finding that nematodes produce ‘milk' for their young, and explain why president-elect Joe Biden is providing renewed hope for tackling the climate crisis. On the pod this week are Rowan Hooper, Cat de Lange, Leah Crane and Donna Lu. To read more about the stories, subscribe at newscientist.com/podcasts.The podcast and artwork embedded on this page are from New Scientist, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.

West Coast Cookbook & Speakeasy is Now Open! 8am-9am PT/ 11am-Noon ET for our especially special Daily Specials; Blue Moon Spirits Fridays!Starting off in the Bistro Cafe, Trump's corrupt pardon of Flynn must be court-challenged.Then, on the rest of the menu, the lame duck Trump administration will appeal a court order barring the expulsions of migrant children seeking asylum; a prominent Washington lawyer defending Steve Bannon against border wall fraud charges, has dropped out of the case; and, New York Governor Andrew Cuomo dismissed the US Supreme Court's religious gatherings ruling as, 'irrelevant.'After the break, we move to the Chef's Table where the UK asked its medicine regulator to assess the AstraZeneca-Oxford vaccine amid questions about preliminary results from the trials; and, a Cambodian court began hearing the cases of nearly one hundred thirty government critics charged with treason for taking part in nonviolent political protests.All that and more, on West Coast Cookbook & Speakeasy with Chef de Cuisine Justice Putnam.Bon Appétit!~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~“Structural linguistics is a bitterly divided and unhappy profession, and a large number of its practitioners spend many nights drowning their sorrows in Ouisghian Zodahs.” ― Douglas Adams "The Restaurant at the End of the Universe"~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~Show Notes & Links: https://www.dailykos.com/stories/2020/11/27/1998518/-West-Coast-Cookbook-amp-Speakeasy-Daily-Special-Blue-Moon-Spirits-Fridays

23 de novembro de 2020 • Episódio #139 do podcast Economia em Tempos de Pandemia, por Monica de Bolle.

The COVID vaccine race has faced a hurdle, after a participant in the Oxford-AstraZeneca trials developed neurological symptoms, prompting the company to pause the trials voluntarily. Health care news publication Stat reported that the participant was a woman from the and she did receive the vaccine as opposed to a placebo and that her symptoms were similar to a rare but serious spinal inflammatory disorder called transverse myelitis. Now the AstraZeneca-Oxford research has been the frontrunner in the global race for a COVID-19 vaccine as we know, and this hurdle has triggered a global shutdown of the phase 2 and phase 3 trials. As questions are rife on social media over this development, are these snags normal or does this call for a re-assessment of this vaccine race? And secondly, what's the road ahead on the trial timeline? Tune in to The Big Story!Producer and Host: Shorbori PurkayasthaGuests: Professor Giridhar R. Babu, Head of Lifecourse Epidemiology at the Public Health Foundation of India Editor: Shelly Walia Music: Big Bang FuzzListen to The Big Story podcast on: Apple: https://apple.co/2AYdLIl Saavn: http://bit.ly/2oix78C Google Podcasts: http://bit.ly/2ntMV7S Spotify: https://spoti.fi/2IyLAUQ Deezer: http://bit.ly/2Vrf5Ng Castbox: http://bit.ly/2VqZ9ur

So… no video this morning. Why not? Well… after the show it turns out that I had a case of TCD. Which once upon a time caught us on the USS Michigan. And now it's catching all the Facebook School Medicine graduates who are taking time out of their busy patient schedules to inform me that AstraZeneca-Oxford is “wrong” to halt its Phase III Cornonavirus vaccine trials…

In this episode, we talk to a data and privacy law specialist Emma Sadleir on the skepticism surrounding Covid-19 contact tracing apps and Professor Shabir Madhi, one of South Africa's pre-eminent experts on vaccines. Professor of Vaccinology at the University of the Witwatersrand, he has published more than 350 studies in his field. Professor Madhi speaks to us about the latest developments in Covid-19 vaccine trials, including the news that the AstraZeneca Oxford trial has been temporarily put on hold. And he shares the details of a study that explores the possibility that South Africans may have developed immunity to Covid-19 as a result of exposure to other, similar diseases. Professor Madhi also sets out how the pandemic might develop - and says he disagrees that SA has a low Covid-19 death rate.

In this episode, we talk to a data and privacy law specialist Emma Sadleir on the skepticism surrounding Covid-19 contact tracing apps and Professor Shabir Madhi, one of South Africa's pre-eminent experts on vaccines. Professor of Vaccinology at the University of the Witwatersrand, he has published more than 350 studies in his field. Professor Madhi speaks to us about the latest developments in Covid-19 vaccine trials, including the news that the AstraZeneca Oxford trial has been temporarily put on hold. And he shares the details of a study that explores the possibility that South Africans may have developed immunity to Covid-19 as a result of exposure to other, similar diseases. Professor Madhi also sets out how the pandemic might develop - and says he disagrees that SA has a low Covid-19 death rate.

Early reports revealed AstraZeneca's vaccine generates antibodies and T-Cells in the Oxford University phase 1 trial. The official data and results are set to be published today and could have a huge impact on the stock market.

Large study finds drug touted by Trump is “not useful and may be harmful” for COVID-19 patients. Trump declares churches ‘essential,' calls on them to reopen. California rushes to aid virus-stricken border region. AstraZeneca-Oxford trial COVID vaccine moves to crucial phase with $1 billion in U.S. backing. The post COVID-19 Daily Brief for May 22nd, 2020 appeared first on COVID 19: Daily Brief.